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Cone snail venom is a mixture of disulfide-constrained peptides (conotoxins), 
hormone-like peptides, and proteins that have been ‘weaponized’ for predation and 
defense. Venom peptides, or conopeptides, have efficiently evolved to bind receptors and 
ion channels that modulate the neuromuscular, cardiovascular, and central nervous 
systems in prey species. With over 850 species of cone snails, each with unique venom 
concoctions, cone snail venom is a valuable source of novel pharmacological probes and 
potential drug leads. However, the complexity of the venom poses a challenge for drug 
discovery. Contributing to the complexity is 1) a wide range in molecular weight 2) peptide 
hyper-variability by post-translational modifications and 3) many potential molecular 
targets to pursue. In this research, a ‘venomics’ approach was employed for the global 
identification of venom components. This ‘venomics’ methodology combines RNAseq data 
from the venom duct and proteomic data from raw injected venom to identify novel 
conopeptides.  
This project was a data-driven effort to define the venom components of the cone 
snail, Conus purpurascens, and to stimulate further hypothesis-driven studies. First, 21 
new base conopeptides were identified from the injected venom of Conus purpurascens, 
a fish-hunting cone snail native to the Pacific coast of Central America. The molecular 
targets were projected based on homology to previously characterized conopeptides. The 
newly identified conopeptides included α-conotoxin, α-PID. Alpha-conotoxins are 
inhibitory ligands of nicotinic acetylcholine receptors (nAChRs), and the most ubiquitous 
venom components across the Conus genus. Ligands of nAChRs are clinically important 
for addiction, cognitive disorders, neurodegenerative diseases, and pain. Functional 
characterization of α-PID and three other α-conotoxins was performed to test their activity 
on different nAChR subtypes using heterologous receptor expression and molecular 
modeling techniques. A unique insulin-like peptide (Con-Ins P1) was also identified and 
was the first instance of an insulin-like peptide identified directly from injected venom. This 
research demonstrates how discovery-based ‘venomics’ workflows can be used to yield 


















1.1 Venom in drug discovery 
The world’s most poisonous animals, which include snakes, scorpions, jellyfish, octopi, 
and cone snails, all use venom for predation and defense. Venom is a complex mixture of 
peptides and proteins that have evolved across the animal kingdom. While envenomation 
strategies may differ across clades, the venom protein scaffolds are highly conserved for 
the unified goal of paralyzing prey. Venom peptides and proteins target a wide range of 
pharmacological targets to accomplish this goal, and because of this, humans continue to 
use and study venom for medicinal purposes [2]. There are a few drugs on the market 
derived from venom that fall under the following therapeutic categories: ACE inhibitors 
(captopril), anti-platelet drugs (eptifibatide and tirofiban), thrombin inhibitors (lepirudin and 
bivalirudin), type-2 diabetes drugs (exenatide), and pain killers (ziconotide) [3].  
Chlorotoxin from the deathstalker scorpion, Quinquestriatus hebraeus, binds chloride 
channels with high affinity. Chlorotoxin has unique selectivity for tumor cells, and when 
attached to a fluorescent dye (Tumor Paint®, Blaze Biotech, Seattle) allows surgeons to 
visualize tumors using infrared glasses [4]. Tumor Paint® is currently undergoing clinical 
trials for use during surgical removal of brain, breast, and skin cancers. Dalazatide (Kineta, 
Seattle), a voltage-gated potassium channel blocker (Kv1.3) from the Caribbean sun 
anemone (Stichodactyla helianthus), is currently being developed for the treatment of 
autoimmune diseases. Phase I trials showed positive results against psoriasis [5] and is 
now being tested for rheumatoid arthritis, lupus, and type 1 diabetes. There are also 
several venom peptides in preclinical development for pain, including tarantula-derived 
sodium channel blockers (Nav1.7) [6] and conotoxin RgIA [7]. Therapeutic applications of 
conotoxins will be discussed in-depth in the following section.  
The biggest obstacle when developing venom components as drugs is their 
bioavailability. This results from their relatively large size, compared to small molecule 
therapeutics, and their hydrophilic nature, rendering them incapable of crossing biological 
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membranes to reach their molecular targets. These barriers include the blood-brain barrier 
and intestinal walls [2, 8]. Venom toxins under drug development commonly require 
peptide engineering to improve bioavailability. One successful mechanism is the 
cyclization of conotoxins by linking the N- and C- termini [9-11]. Another option is to 
synthesize smaller toxin analogs that maintain the functional group of the peptide but 
improve bioavailability. Post-translational modifications (PTMs), such as glycosylation, 
have also been shown to improve peptide permeability through biological membranes [12].  
One group of peptides that have had success as pharmaceutics are the cysteine knot 
peptides, miniprotein scaffolds restrained by multiple disulfide bonds [13]. Included in this 
family are the knottins, which have six cysteine residues 
and a specific disulfide pairing between cysteines 1 and 
4, 2 and 5, and 3 and 6 (Figure 1). Cysteine knot peptides 
are naturally produced by animals, plants, and fungi, but 
the knottins are found most prominently in cone snail and 
spider venom [14]. More recently, knottin peptides have 
also been described from anemone venom and 
marine sponge tissue [15, 16]. 
Two FDA approved drugs are derived from 
naturally occurring cysteine knot peptides, linaclotide (Linzess®, AbbVie and Ironwood 
Pharmaceuticals, Inc.) from the endogenous hormone guanylin [17] and ziconotide 
(Prialt®, TerSera Therapeutics, LLC) from conotoxin ω-MVIIA [18]. Factors contributing to 
cystine knot peptide success as drugs include their thermal, chemical, and proteolytic 
stability [19]. Their resistance to proteases allows these peptides to remain intact in 
biological environments, including the gastrointestinal tract, thereby increasing their 
bioavailability and likelihood of availability through oral administration [20]. This is not the 
case for ziconotide, a conotoxin-based drug for chronic pain that is administered 
Figure 1- Knottin peptide 
structure and disulfide pairing. 
Adapted from Kintzing et al. 2016 
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intrathecally through an infusion pump due to its low oral bioavailability. As we continue to 
discover venom peptides with clinically relevant targets, the knottin miniprotein scaffolds 
will require substantial engineering efforts and improved drug delivery mechanisms. 
1.2  Conopeptides and their therapeutic applications  
Conopeptides are a diverse group of rapidly evolving gene products found in cone 
snail venom that range in size, structure, and molecular target. They work synergistically 
to immobilize prey/predators. Positive selection through point mutations, alternative 
splicing, and post-translational modifications (PTMs) has created a rich source of bioactive 
peptides that target membrane receptors with high specificity [21-23]. The molecular 
targets are used to classify the conopeptides into pharmacological families (Table 1) [24, 
25]. Their targets include voltage-gated and ligand-gated ion channels, G-protein-coupled 
receptors, and neurotransmitter transporters, all with important clinical implications.  
Several conopeptides have successfully reached clinical trials (Table 2). Although 
conopeptides have a broad range of therapeutic targets, their high specificity for neuronal 
receptors make them particularly apt for pain treatment [26, 27]. Overuse and 
overprescribing of opiate-based pain killers have resulted in a current opiate crisis [28]. 
There is a severe need for alternative, non-opiate pain management treatments. 
Conopeptides are a promising source of novel pain medications without the risk of 












αS- conotoxin VIII C-C-C-C-C-C-C-C-C-C 
αD- conotoxin XX C-CC-C-CC-C-C-C-C 
Ψ- conotoxin allosteric inhibitor III CC-C-C-CC 
σ- conotoxin 5HT3R inhibit channel VIII C-C-C-C-C-C-C-C-C-C 
μ- conotoxin 
Na+ channel 
inhibit channel III CC-C-C-CC 
μO- conotoxin inhibit conductance VI/VII C-C-CC-C-C 
δ- conotoxin delay inactivation VI/VII C-C-CC-C-C 





κJ- conotoxin XIV C-C-C-C 
κM- conotoxin inhibit channel III CC-C-C-CC 
κO- conotoxin shaker K+ inhibit channel VI/VII C-C-CC-C-C 
χ- conotoxin NE transporter inhibit transporter I/X CC-C-C 
Conantokin NMDA receptor ---  
 
Contulakin Neurotensin receptor Agonist  
 
Conopressin Vasopressin receptor Agonist  C-C 
conoCAPS  cardioactive peptide  C-C 




Conopeptide Species Target Application Status 
MVIIA C. magus Cav2.2 Pain FDA approved, 
2004 
CBID C. catus Cav2.2 Pain discontinued 
MrIA C. marmoreus Norepinephrine 
transporter 
Pain discontinued 
Contulakin-G C. geographus Neurotensin receptor Pain discontinued 
Conantokin-G C. geographus NMDA receptor Pain, epilepsy discontinued 
Vc1.1 C. victoriae α9α10 nAChR Pain discontinued 
RgIA4 C. regius α9α10 nAChR Pain preclinical 
 
Thus far, Ziconotide is the only conotoxin-derived drug approved by the FDA (PrialtTM) 
and is the only venom peptide approved for the management of intractable pain. 
Ziconotide is a non-opioid, non-NSAID analgesic that blocks CaV2.2 subtype calcium 
channels [29]. It was developed from the conotoxin MVIIA from Conus magus. Ziconotide 
requires an intrathecal drug delivery system because of its inability to pass the blood-brain 
barrier and is therefore not an optimal alternative for chronic pain management.  
Contulakin-G, a neurotensin receptor antagonist from Conus geographus, was tested 
previously in a clinical trial for severe chronic pain. Vc1.1 from Conus victoriae, a nicotinic 
receptor inhibitor, went to a Phase 2 clinical trial for neuropathic pain associated with 
sciatica and diabetic neuropathy [30, 31]. Another nicotinic receptor inhibitor, RgIA4, an 
analog of α-conotoxin RgIA from the venom of Conus regius, is currently in preclinical 
development for neuropathic pain [3, 32]. Vc1.1 and RgIA both inhibit nicotinic receptors 
[33], but conflicting evidence suggests that their analgesic effect is through the GABAB 
receptor [34, 35]. In this proposed study, we aim to identify venom peptides that target 




Table 4- Conopeptides that reached human clinical trial as pain therapies. 
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1.3  Nicotinic acetylcholine receptors: structure and function 
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels responsible 
for neurotransmitter signaling at the synaptic gap and the neuromuscular junction. They 
belong to the Cys-loop superfamily of ligand-gated ion channels, which includes receptors 
gated by acetylcholine, serotonin, GABA, and glycine. All contain a signature cysteine loop 
formed by a disulfide bond joining adjacent subunits [36, 37]. Initial studies on nAChRs 
utilized the receptor-dense electrical organ tissue of Torpedo marmorata (electric stingray) 
[38]. This later allowed cloning and functional characterization of seventeen different 
genes for nAChR subunits (α1-10, β1-4, γ, δ, and ε). Any five of these subunits join to 
form functional pentameric proteins that can be either heteromeric or homomeric.  
Nicotinic receptors are classified into the muscle or neuronal subtypes depending on 
their subunit composition and localization [39]. Muscle subtypes are comprised of α1, β1, 
γ, δ, and ε subunits, and are expressed at the neuromuscular junction. The muscle-type 
nAChRs are critical for skeletal muscle contraction and voluntary movement. Inhibitors of 
muscle-type nAChRs include local anesthetics, such as lidocaine [40], and α-neurotoxins 
that cause paralysis, such as the snake venom toxin, α-bungarotoxin [41]. Neuronal 
subtypes are comprised of combinations of α and β subunits (α2-6 and β2-4) or are 
homomeric (α7-10). Neuronal subtypes are heterogeneously expressed throughout the 
central and peripheral nervous systems where they are involved in neuronal transmission 
and the dopaminergic pathway [42].  
8 
The ligand-binding properties of 
nAChRs have been studied using the X-
ray crystal structure of the soluble 
acetylcholine binding protein (AChBP) of 
mollusks Lymnaea stagnalis and Aplysia 
californica [43]. AChBPs are not functional 
ion channels, however; they form stable 
homopentamers that preserve features of 
the ligand-binding domain of nAChRs and 
thereby serve as useful binding models. 
The ligand-binding pocket is ‘gated’ by a 
loop structure (Loop C) that controls ligand 
activity [44]. Crystallized AChBP 
complexes with select nicotinic agonists and antagonists revealed that agonists bind 
below the C loop causing it to close over the ligand-bound pocket and open the channel 
pore. Antagonists, such as α-conotoxins, cause Loop C to be held in an extended 
conformation away from the ligand-binding pocket [45, 46] (Figure 2). Heteromeric 
receptors have two ligand-binding sites located between adjacent α and β subunits. 
Homomeric receptors have five ligand-binding sites located between each α subunit [47]. 
Ligands of neuronal nAChR subtypes are clinically important as treatments for 
addiction, cognitive disorders, neurodegenerative diseases, and pain [48]. However, there 
are few compounds available that target neuronal subtype nAChRs with high selectivity. 
To explore the physiological role of neuronal-type receptors, we need highly selective 
pharmacological probes. Alpha-conotoxins are the first group of peptide α-neurotoxins that 
show selectivity for neuronal subtype nAChRs and are therefore extremely valuable 
research tools and pharmacological agents [49, 50].  
Figure 2- Overlay of AChBP subunit with 
muscle-type nAChR α-subunit. AChBP 
subunit (blue) with muscle-type nAChR α-
subunit (gray) (Hansen, 2005). N-terminal 
(N), C-terminal (C), ligand-binding domain 
(Loops B,C,F).   
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1.4  Alpha-conotoxins: ligands of the nAChR 
Alpha-conotoxins are inhibitors of the nAChR and are the most ubiquitous venom 
components across the Conus genus. All species analyzed express one or more α-
conotoxins in their venom that work synergistically to paralyze prey. Unique from other 
nAChR ligands, α-conotoxins exhibit remarkable subtype selectivity, specifically among 
neuronal receptor subtypes  
Alpha-conotoxins can display different cysteine frameworks, or patterns of cysteine 
residues within a sequence (Table 1). Framework I α-conotoxins belong to the A 
Superfamily, as defined by a conserved gene signal sequence. This is the largest group 
of characterized α-conotoxins with the greatest diversity in subtype selectivity. The post-
translational modifications commonly found on these conotoxins (C-terminal amides and 
hydroxyprolines) are important for peptide stability and bioactivity [51]. In our study, we 
will be focusing on framework I α-conotoxins because of their relatively small size (<22 
amino acids) and because of their well-established disulfide connectivity (C1-C3, C2-C4) 
[52]. The fact that they have only two disulfide bonds with established pairing makes these 
peptides good candidates for chemical synthesis, which is necessary to perform functional 
assays.  
Within the framework I α-conotoxins, 
there is significant diversity in amino acid 
composition and the size of the inter-
cysteine loops. Inter-cysteine loop size 
affects affinity toward either muscular or 
neuronal nAChR subtypes (Figure 3) [53, 54]. In general, α-conotoxins exhibiting a 3/5 
inter-cysteine loop pattern are inhibitors of neuromuscular junction subtypes, and 4/3 and 
4/7 toxins inhibit neuronal subtypes [55]. To date, there are very few 4/4 α-conotoxins 




characterized. Of the ones known, α-BuIA inhibits neuronal receptors containing α3, α6, 
and β2 subunits, whereas α-PIB and α-PIC preferentially inhibit muscle subtypes. 
Neuronal nAChR subtypes are expressed heterogeneously throughout the central 
nervous system [56] and are implicated in a range of neurological conditions (Figure 4). 
The most widely expressed 
subtype in the mammalian brain, 
α4β2, is heavily involved in the 
dopaminergic pathway and 
nicotine addiction. This receptor 
can exhibit different subtype 
stoichiometry; (α4)2(β2)3 is more 
sensitive to nicotine than 
(α4)3(β2)2 [57]. Because of its 
role in nicotine addiction, α4β2 is the clinical target for smoking cessation therapies, 
including the partial agonist, varenicline (Chantix, Pfizer, Inc.). Very few α-conotoxins 
inhibit α4β2, with α-GID being the most potent inhibitor. Amino acid substitution studies 
on α-GID deemed A10, V13, and V18 as critical residues for α4β2 selectivity [58]. 
Of the neuronal subtypes, the α3β2 receptor is the most common α-conotoxin target. 
LvIA is the first α3β2 subtype-selective conotoxin. The Asp11 residue is responsible for 
selectivity over α6-containing subtypes [59]. The selectivity of α-PnIA for α3β2 over its 
alternative α7 target is dependent on Ala10 [60].  
The α3β4 subtype is the predominant nAChR in the sensory and autonomic ganglia 
neurons. It is expressed in the mesolimbic dopamine circuitry of the midbrain where it 
modulates addiction to nicotine and potentially other drugs of abuse [61, 62]. AuIB is an 
α3β4 selective toxin with an uncommon 4/6 inter-cysteine loop size. The Phe9 residue 
regulates subtype selectivity [63]. Ligands with α3β4 selectivity will help better understand 
Figure 4-Neuronal subtypes of nAChRs and their 
clinical applications. 
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the role of these receptors in the midbrain and may be useful therapeutics for addiction 
[64]. 
The α6-containing subtypes are also expressed abundantly in the midbrain 
dopaminergic neurons and are mediators of the nicotine reward pathway [65, 66]. Ligands 
with selectivity for α6-subtype nAChRs are important molecular probes to study the 
pathophysiology of addiction and other dopamine-related disorders, such as Parkinson’s 
disease.  However, α6 selectivity is rare because of its high homology with the α3 subunit. 
There is one α6-biased ligand, α-PIA from C. purpurascens, known thus far. α-PIA 
preferentially inhibits α6-containing receptors with a 75-fold greater affinity than α3 
receptors [67, 68]. α-MII from C. magus is an α3-selective ligand, but alanine substitution 
studies distinguished α-MII analogs with significantly increased affinity α6 over α3 [69], 
shedding light on structural determinants of α6 selectivity. 
Homomeric α7 nAChRs are a unique subtype expressed throughout the brain and in 
non-neuronal tissues, like immune cells [70]. Their distribution in the brain includes the 
hippocampus and cerebral cortex involved in learning and memory [71]. The α7 receptor 
is unique in that agonist binding elicits a relatively low ion current and becomes easily 
desensitized, compared to heteromeric subtypes. The α7 receptors also bind highly-
selective molecules called positive allosteric modulators (PAMs) that significantly enhance 
agonist-induced ion currents, but have no effect alone (reviewed in [39]). Conotoxin α-
MrIC is the first described selective α7 agonist that can activate, rather than inhibit, α7 
receptors in the presence of PAMs (65). It is thereby a useful tool in studying the kinetics 
and function of this unique receptor subtype. 
The α9 homomeric receptor is another unique, and perhaps the most elusive, nAChR 
subtype. It is expressed in cochlear hair cells and periphery epithelial and immune cells 
[42]. The α9 subunit can co-express with α10 to form functional ion channels, and elicit 
ACh-evoked currents 100-fold stronger than homomeric α9 receptors [72]. Both α9 and 
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α9α10 are thought to be involved in pain pathways [73]. The α-conotoxins Vc1.1 (4/7) and 
RgIA (4/3) both elicit analgesia through inhibition of α9α10 nAChRs [32, 73]. As an 
effective anti-nociceptive target, α9 nAChRs offer an alternate non-opioid pathway for pain 
treatment that needs to be explored. 
1.5  Impact  
The identification of venom components has increased rapidly with the advancement 
in next-generation sequencing technologies and bioinformatics tools. Venomics is the 
hybridization of RNAseq and proteomic analysis to study venom and identify its 
components. Venomics enables high-throughput discovery of venom peptide and protein 
sequences [74-76].  
Venomics methodology supersedes previous chemical-based or bioassay-guided 
fractionation for natural product discovery. These traditional discovery methods require 
multiple biological assays or elaborate chemical elucidation schemes to find a single 
compound of interest. The workflow established in this proposed research project can be 
modified to discover novel active peptides from any venomous animal. This project will 
also provide information on novel α-conotoxin activity on multiple nAChR subtypes with 
important clinical applications. Specifically, α-conotoxins have proven to be good 
candidates for non-opiate pain treatment and have made it to clinical trials. To combat 
our current opiate crisis and regulate the over-prescription of opiate medications, we must 
have safe and effective alternatives for pain management. 
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2.1  Cone snail specimens 
2.1.1 C. purpurascens specimens and venom collection 
Specimens of C. purpurascens (n = 27) 
were collected from the Pacific coast of 
Costa Rica. C. purpurascens was chosen 
for this intraspecific venom analysis 
because it is a fish-hunting species that 
uses a hook-and-pull strategy to capture 
prey allowing venom collection through a 
“milking” procedure [31]. Briefly, venom is 
collected into Eppendorf tubes that have a piece of latex glove stretched over the opening 
and are baited with a piece of goldfish fin on the latex. When the snail senses the fin, it 
spears the latex and injects venom into the tube (Figure 5). After the venom is released, 
the snail is fed with a live fish. Snails were kept in an aquarium facility where they were 
fed and milked regularly. The injected venom samples were stored at -80 °C until used for 
further analysis. 
2.1.2 Other Conus species 
Venom ducts were also dissected for downstream RNASeq from the following Conus 
species: C. striatus, C. vanhyningi, C. brunneus, C. spurius, C. princeps, C. regius, C. 
gladiator, C. lindae, C. arangoi, C. moreleti, C. nussatella, C. richardbinghami, C. 
leopardus, C. caysalenensis, C. granulatus, C. dalli, C. anabathrum. 
2.2  Tissue dissection and RNA sequencing 
Venom ducts were dissected from two C. purpurascens snails, specimens 1 and 14. 
The venom ducts were immediately placed in RNAlater (Invitrogen), and stored at -80° C. 
mRNA was extracted from the venom duct using an RNeasy Lipid Tissue mini kit (Qiagen), 
and mRNA quality was confirmed with a 2100 Bioanalyzer (Agilent). Illumina libraries were 
Figure 5- Venom milking from  
C. purpurascens. 
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prepared with a NEBNext Ultra Directional RNA Library prep kit (New England BioLabs). 
Sequencing was performed on a NextSeq 500 platform (Illumina, Inc.) and each venom 
duct yielded approximately 28 million paired-end reads (75 bp).  
2.3  Bioinformatics 
2.3.1 Transcriptome assembly 
Raw reads for each venom duct were assembled with Trinity de novo transcript 
assembler (v. 2.2.0) using default parameters; group pairs distance: 500 bp, path 
reinforcement distance: 75 bp [33]. The resulting transcriptomes (A and B) were translated 
with EMBOSS applications, transeq (6-frame) and getorf (between start and stop codons) 
[34, 35] (Table 3). Transcriptomes were interrogated for conotoxin expression. 
2.3.2 Conopeptide interrogation 
The Trinity de novo assemblies (transcriptomes A and B) were translated with transeq 
and getorf, and resulting transcripts were blasted (blastp, e = 10-5) against the UniProt 
Animal Toxin Annotation database (ToxProt) and all UniProt Conus entries (TaxID: 6490) 
to extract toxin-like sequences. The resulting sequences were developed into databases 
for proteomic searches (described in detail in Section 2.5). Transcript quantification (TPM) 
for conopeptides from the C. purpurascens venom duct transcriptomes was performed 
with Salmon [30] using the Trinity assembly as the reference transcriptome (kmer length 
= 31). 
2.3.3 Insulin-like peptide interrogation 
The translated FASTA files were interrogated for conoinsulin sequences using 
BLASTp search function (e= 10) with a conoinsulin query database that included all 
conoinsulin sequences from UniProt. Transcript quantification (TPM) for conoinsulins from 
C. purpurascens tissues was performed with Salmon [30] using the Trinity assembly as 
the reference transcriptome (kmer length = 31). 
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A phylogenetic analysis of ILPs was performed using insulin superfamily proteins 
obtained from the InterPro database (IPR036438). Taxonomy IDs were extracted and 
submitted to NCBI Taxonomy Browser- Common Tree to generate a phylip tree. The 
phylip tree file was imported into Geneious 2020.1.1 (Biomatters, Ltd., Auckland, NZ) to 
create a phylogenetic tree. ILPs from all Conus sp. were extracted from the InterPro 
database (IPR036438) and aligned using Clustal omega within Geneious software.  
2.4  Mass spectrometry analysis of venom samples 
An aliquot of each venom sample (5 µL) was diluted in ammonium bicarbonate buffer 
(50 mM). Cysteine bonds were reduced with dithiothreitol (7 mM) for 1 h at 60 °C and 
alkylated with iodoacetamide (18 mM) for 1 h at 21 °C in the dark. Following reduction and 
alkylation, the samples were desalted using C18 spin columns (ThermoFisher Pierce) and 
lyophilized before LC-MS/MS analysis. 
Samples were reconstituted in water/0.1% formic acid and analyzed by LC-MS/MS on 
an Orbitrap Fusion Lumos trihybrid mass spectrometer (ThermoFisher Scientific) coupled 
with an UltiMate 3000 RSLCnano System (ThermoFisher Scientific). A 160 min gradient 
with solutions A (5% acetonitrile/ 0.1% formic acid) and B (80% acetonitrile/ 0.1% formic 
acid) on an Acclaim PepMap 2μm C18 column (75 μm x 25 cm) (ThermoFisher Scientific) 
was used. The flow rate was set at 0.3 μL/min with the following gradient steps: 0 min at 
5% B, 10 min at 5% B, 115 min at 27.5% B, 130 min at 40% B, 140 min at 95% B, 150 
min at 5% B, 160 min at 5% B.  
MS1 scans (200-2000 m/z) were collected with an Orbitrap mass analyzer at a 
resolution of 120,000 using quadrupole isolation; RF lens 30%, AGC target 4.0e5, and a 
50 ms injection time. Precursor ions were fragmented using HCD (32%). MS2 scans were 
collected with an Orbitrap resolution of 30,000 using quadrupole isolation and AGC target 
2e4. A charge state filter was used (+2-6) and the intensity threshold was set to 2e4. 
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Dynamic exclusion was set to exclude precursor ions for 60 s after collecting 10 MS2 
scans within 30 s.  
2.5  Database configuration and search parameters 
Several databases were configured and assessed for completeness before choosing 
the best search database for the 27 venom samples. The database was optimized for 
time-intensive non-enzymatic searches with many PTMs using the following criteria; 
inclusivity of conopeptide-encoding transcripts and the total number of entries. We 
compared the following four database configurations, all from the de novo transcriptome 
assemblies of venom duct RNAseq data. 1) The de novo assembly was blasted (blastX, 
e = 10-5) against the UniProt Animal Toxin Annotation database (ToxProt) and all UniProt 
Conus entries (TaxID: 6490), then translated ORFs were extracted with getorf, and 
complete transcripts with signal sequences were extracted with SignalP v4.0 [77].  2) The 
de novo assembly was blasted as previously described using blastX, then the hits were 
translated with transeq, and only transcripts containing > 4 cysteines were extracted. 3) 
The de novo assembly was translated, the ORFs were extracted with getorf, and complete 
transcripts with signal sequences were extracted with SignalP (this configuration did not 
include a blast step). 4) Trinity assembly was translated with transeq and getorf, and 
resulting transcripts were blasted (blastp, e = 10-5) against the ToxProt database to extract 
toxin-like sequences. We chose the ToxProt-guided configuration (4) as the optimal 
search database, to which we added a customized C. purpurascens database that 
included conopeptide sequences not present in the transcriptomes (Table 3, Figure 6). 
The additional C. purpurascens database included previously identified peptides from 
UniProt (taxid: 41690) and unpublished conopeptide sequences identified in-house using 
the PEAKS de novo search algorithm (Bioinformatics Solutions Inc., Ontario, Canada) 
[78]. PEAKS can deduce peptide sequences from MS/MS spectra without a database. 
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PEAKS scored the predicted sequences with an average local confidence (ALC) score. In 
the in-house C. purpurascens database, only predicted conopeptide sequences with ALC  
scores greater than 98% were included. 
Database searches were performed with the Sequest algorithm within Proteome 
Discoverer v2.0 (Thermo Fisher Scientific). Search parameters included a mass error of 
10 ppm for precursor peptides and 0.02 Da for fragment ions. Fixed modification, 
Carbamidomethyl (C), was introduced and several previously reported conotoxin PTMs 
were introduced as variable modifications: oxidation (M/P), carboxylation (E), bromination 
(W), deamidation (N/Q), pyroglutamate (N-terminus), and amidation (C- terminus). The 
false discovery rate (FDR) threshold was set to 1% using a decoy database. Only high 
and medium confidence protein matches were considered for downstream analysis. 
 
Sequence File Description # Sequences 
1. Transcriptome A Assembly of RNA-seq data from specimen 1  83,051 
2. Transcriptome B Assembly of RNA-seq data from specimen 14  84,410 
3. Translated– getorf  Files 1 and 2 translated with getorf   231,175 
4. Translated– transeq  Files 1 and 2 translated with transeq   1,004,766 
5. ToxProt BLAST hits Files 3 and 4 blasted against ToxProt database  1,652 
6. C. purpurascens 
Database 
C. purpurascens conopeptides including UniProt 
entries (taxid: 41690) and de novo sequences 
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Table 3- Search database file descriptions. 
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2.6  Hierarchal cluster analysis and Principal Component Analysis 
Total intensities for each conopeptide were normalized to the highest intensity within 
each sample. Total intensities were normalized in this analysis to account for differences 
in protein concentration between venom samples. Hierarchal clustering and Principal 
Component Analysis were performed using ClustVis online software (v. 2018-12-20) [38]. 
Normalized intensities were log-transformed (ln(x + 1)) prior to hierarchal cluster analysis. 
Hierarchal clustering was employed on both x- and y- axes using Pearson correlation 




Figure 6- Workflow of the database search strategy. 
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2.7  Alpha-conotoxin testing on nAChR subtypes 
2.7.1 Alpha-conotoxin identification, selection, and synthesis 
To identify putative α-conotoxin sequences, a conserved gene signal sequence was 
obtained from Conoserver.org and used as a search query against the 17 transcriptomes 
(BLASTp, e=10). Mature peptide sequences were predicted using SignalP software and 
the predicted sequences were aligned using Geneious Prime (Biomatters, Aukland NZ). 
From the alignment, we were able to assess inter-cysteine loop sizes and homology to 
other functionally characterized α-conotoxins. Three peptides (α-PID, α-NuxIA, α-CedIA) 
were chosen for functional assays on nAChRs and were synthesized by solid-state 
synthesis through a third-party company to yield milligram quantities (GenScript, 
Piscataway, NJ). The following post-translational modifications were incorporated: 
disulfide bonds between C1-C3 and C2-C4 and amidation of the C-terminal. Once 
received, peptide purity was confirmed by RP-HPLC separation on a C18 column. α-PIA 
is commercially available and was purchased for functional screening (Alamone Labs, 
Jerusalem, Isreal).  
2.7.2 Oocyte harvesting and injection 
Nicotinic receptor subtypes were heterologously expressed in Xenopus laevis oocytes. 
Frogs were maintained in the Animal Care Service facility of the University of Florida, and 
all protocols were approved by the University of Florida Institutional Animal Care and Use 
Committee. First, oocytes were surgically removed from female frogs. The oocytes were 
then injected with cRNA for the nAChR subunits required for the expression of one of 
seven different receptor subtypes (Table 4). After injection, the oocytes were stored in 
Barth’s solution (88 mM NaCl, 1 mM KCl, 2.38 mM NaHCO3, 0.82 mM MgSO4, 15 mM 
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2.7.3 Two-electrode voltage-clamp recordings 
Two-electrode voltage-clamp experiments were performed on an OpusXpress 6000A 
using pClamp software (Molecular Devices, San Jose, CA). Oocyte membrane potential 
was clamped at -60 mV and bath-perfused with Ringer’s solution (115 mM NaCl, 2.5 mM 
KCl, 1.8 mM CaCl2, 10 mM HEPES, and 1 μM atropine, pH 7.2). Membrane current (μA) 
was recorded throughout the following experimental protocol: pre-control (ACh), treatment 
application (α-CNTX), co-application (ACh + α-CNTX), and post-control (ACh). ACh 
controls were administered before and after α-conotoxin treatments to establish the oocyte 
baseline response to ACh and the oocyte viability and receptor desensitization after 
treatment. The ACh control concentration for each receptor subtype is reported in Table 
4. 
 
Table 4- NAChR subtypes with associated subunit RNA and ACh controls used 
for voltage-clamp experiments.  
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2.7.4 Data analysis and IC50 calculation 
Each experiment will have a sample size of 4-8 oocytes. Individual oocyte recordings 
were eliminated from analysis if they were 1) unresponsive to the ACh pre-control 2) lost 
their ‘clamp’ or holding potential (60mV) during the experiment or 3) had significant 
desensitization to the post-control. Analysis of recordings was performed with Clampfit 
software (Molecular Devices, San Jose, CA). Treatment response was measured as peak 
current amplitude (μA). For each oocyte, the values for treatment response were 
normalized to the ACh controls to account for differences in receptor expression levels 
and ACh responsiveness between oocytes. T-tests were performed (n ≥ 3) for each 
treatment on each nAChR subtype to test the hypothesis that the response of ACh controls 
will be different from α-conotoxin + ACh treatments (p≤0.05). IC50 values were calculated 
using an inhibitory dose-response curve nonlinear regression model with the following 
equation: Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)). When comparing α-
PIA and α-PID dose-response curves the hill slope was constrained to -1 with the 
assumption that their binding mechanisms to the nAChR are similar.  
2.7.5 Homology modeling of the human α7 nAChR 
The structure of the α-PIA and α-PID bound to the human α7 nAChR (hα7) was 
modeled based on the co-crystal structure of Aplysia californica AChBP bound to 
conotoxin LvIA (PBD: 5XGL). First, the sequence of the extracellular domain of hα7 was 
obtained from Uniprot (ID: P36544). An alignment file was created by aligning the hα7 and 
α-PIA/α-PID sequence to the AChBP and LvIA sequence using the Clustal Omega 
alignment algorithm within Geneious Prime (Biomatters, Aukland, NZ). Homology 
modeling was performed using MODELLER (version 9.24) (University of California San 
Fransisco)[79]. The resulting PDB files were visualized using UCSF ChimeraX software 
[80] and analyzed for molecular energy and residue contact distances using Molecular 
Operating Environment (MOE) (Chemical Computing Group, Montreal, Canada).   
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3.1  Introduction 
Venomous animals comprise over 200,000 species across several taxa and display a 
variety of mechanisms for venom production, delivery, and use [81]. For most animals, 
venom is proteinaceous; however, different taxonomic groups independently evolved to 
produce highly adapted venom as a solution to environmental pressures, a clear example 
of convergent evolution. Most venoms are complex mixtures of peptides, proteins, and 
small molecules that might act in concert to immobilize prey or deter predators. The 
specific molecular content of these composites varies from phyla, class, order, family, and 
genus. There can be also significant venom variability within the same species [82-90]. In 
some cases, venom varies within the individual specimens [83, 91-95], as some animals 
can switch their venom from predatory to defensive concoctions. Intraspecific venom 
plasticity expands the molecular adaptations of venomous animals and in doing so 
augments the remarkable repository of compounds with numerous applications that 
include the development of pharmaceuticals, such as Captopril from the Brazilian pit viper 
venom, Exenatide from the Gila monster, and Ziconotide/PrialtTM from cone snail venom 
[3]. 
The venom found in marine predatory snails belonging to the genus Conus (cone 
snails) has been intensely studied in terms of content and pharmacological properties. 
Most notable are the conotoxins, a diverse group of disulfide-constrained (two or more 
disulfide bonds) peptides that target ion channels, ligand-gated receptors, and 
transporters with high affinity and selectivity [96, 97]. Conus venom can also contain linear 
(no disulfides) and one-disulfide bond peptides [98], which along with conotoxins define 
the conopeptides, the full small peptidic complement of the venom of cone snails. 
Conopeptide diversity occurs at both the sequence and post-translational modification 
(PTM) level, resulting in thousands of conopeptides that range in size, chemistry, 
structure, and activity. Conopeptides/conotoxins are classified according to gene 
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superfamilies based on conserved signal sequences, and each superfamily can encode 
hundreds of mature conopeptide sequences [99-101]. Mature conotoxins have displayed 
a plethora of cysteine frameworks and disulfide-bonding patterns, which in turn affects 
activity. Conopeptide complexity also results from a high rate of PTMs [22, 102, 103]. The 
same base peptide can have many differentially modified forms [104, 105], or ‘toxiforms’. 
Conopeptide hyper-modification can be viewed as an evolutionary expansion of venom 
genes used to engineer highly effective and potent toxins. 
The molecular diversity of cone snail venom is extraordinary as its expression is 
species-specific with little overlap of components among the more than 800 extant species 
[106]. This complexity is compounded by intraspecific and intraspecimen venom variations 
due to predatory or defensive venom profiles [90, 91, 93]. This complexity provides a rich 
source of bioactive peptides [107, 108], but it also presents a challenge for venom 
characterization. Intraspecies studies have relied heavily upon comparisons of venom 
chromatography and mass-matching to known venom components, rather than global 
MS/MS spectral matching, to identify venom components. A limitation of this approach is 
that a single base conopeptide sequence can have many toxiforms with different masses. 
This makes it difficult and rather uninformative to assess intraspecific venom variation 
through molecular mass lists alone, and in doing so, it can lead to overestimates of the 
extend of venom variability. Next-generation sequencing technology for RNAseq and 
advances in high-resolution LC-MS/MS have mitigated the challenges associated with the 
analysis of complex venoms and have allowed assessment of the venom 
peptidome/proteome through ‘venomic’ approaches [109, 110].  
A comprehensive analysis of the venom composition is crucial to assess venom 
plasticity and to determine synergistic mechanisms of envenomation used to immobilize 
prey or deter predators. Here, we present a large-scale intraspecific venom analysis of 
Conus purpurascens, the only fish-hunting species of the tropical Eastern Pacific region. 
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Earlier groundwork revealed that C. purpurascens had two distinct venom ‘cabals’, or 
groups of conopeptides acting synergistically to paralyze their prey [89, 111, 112]. The 
cabals act as either 1) a neuromuscular block (motor cabal), targeting nicotinic 
acetylcholine receptors (nAChRs, α- and ψ-conotoxins) and skeletal muscle sodium 
channels (μ- conotoxins) or 2) an excitotoxic neuronal block (lightning-strike cabal), 
targeting neuronal sodium (δ-conotoxins) and potassium channels (κ-conotoxins). 
Previous works, however, were based on mass lists obtained from the venom of a limited 
number of specimens [83, 89]. 
We present a comprehensive venom analysis by utilizing high-resolution LC-MS/MS-
based peptide identification to analyze and compare injected venom from 27 individual 
specimens of C. purpurascens. In doing so, we sought to maximize the identifications of 
conopeptides and their toxiforms. We also assessed the biochemical diversity of the 
venom arsenal by comparing conopeptide expression patterns to gain a more refined view 
of synergistic relationships among the venom components. 
3.2  Results 
3.2.1 Conopeptide identification 
Milked venom samples from 27 specimens of C. purpurascens were analyzed by LC-
MS/MS (Methods Section 2.4) and resulting MS/MS RAW files were searched against a 
FASTA database that consisted of conopeptide sequences either acquired from RNA-seq 
data or deposited in UniProt (www.uniprot.org) (Methods section 2.5). The venom analysis 
yielded 543 unique conopeptide identifications, which included 33 base (or nascent) 
conopeptides and their associated toxiforms (modified versions). Of these 33 base 
conopeptides, 21 sequences were identified here for the first time (Table 5). Detailed 
descriptions of each new conopeptide are provided in Appendix C. Twenty-six of the 
conopeptides were identified through the transcriptome search database (RNA-seq-
assembled transcripts). However, seven conopeptides were identified in the venom but 
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were not found in either of the transcriptomes. Four of these peptides were identified from 
C. purpurascens UniProt entries (α-PIA, α-PIB, κ-PIVF, PVIF), and three conopeptides 
were sequenced de novo and manually added to our in-house search database 
(Contryphan-P4, PIF, and PIG). For the conopeptides that were identified from RNA-seq 
data, full or partial transcripts were used to assign superfamilies through their 
corresponding signal sequence (Table 6). 
The number of base conopeptide IDs per sample of injected venom ranged from 5-17 
(mean= 10.6 ± 2.6) (Figure 7). The most prevalent conopeptide in this population of snails 
was Ile-contryphan-P, identified in 25 of the 27 venom samples. This was followed closely 
by conopeptides κ-PVIIA, PVIIIA, ψ-PIIIE, α-PIVA, and PVIB, all identified in more than 
75% (n > 20) of the venom samples (Figure 8). 
Differentially modified toxiforms were identified for 27 of the 33 base conopeptides 
(Table 5). Toxiforms were only considered if the peptide maintained a complete cysteine 
framework. The PTMs identified through MS/MS analysis included amidated C-terminal, 
hydroxyproline, oxidized methionine, deamidated asparagine/glutamine, 
carboxyglutamate, brominated tryptophan, N-terminal pyroglutamate, and truncations 
from both terminals (Appendix A). The most abundant PTMs were C-terminal amidation 
and hydroxyproline, which occurred on 75% of the base conopeptides identified. The 
same modification(s) occurred on different residues of the same peptide, generating 
unique toxiforms with the same molecular weight. This is the case of hydroxyproline, which 
occurred on up to three residues simultaneously on four peptides: α-PIVA, ψ-PIIIE, PVIE, 
and PVIG. Differential hydroxylation patterns are seen for these conopeptides (Appendix 
A). The greatest PTM variability was observed on A-superfamily conotoxins α-PIVA (98 
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toxiforms) and κ-PIVE (69 toxiforms), and new O1-superfamily conopeptide PVIB (67 
toxiforms) (Table 5).  
Superfamily Conopeptide Sequence Toxiforms 
A α-PIA               RDPCCSNPVCTVHNPQIC 18 
A α-PIB              QSPGCCWNPAC-VKNR—C 6 
A α-PIC               TSGCCKHPAC-GKNR—C 1 
A PID                DPCCSNPACNVNNPQICG 11 
A PIE NAAAKAFDLTAPTAGEGCCFNPACAVNNPNIC 2 
A PIF*               QEPGCCRNPAC-VKHR—C 13 
A PIG*                  PCCSNPVCTVHGGPQLC 2 
A αA-PIVA        GCCGSYPNAACHPCSCKDRPSYCGQ 98 
A κ-PIVE        DCCGVKLEM-CHPCLCDNSCKNYGK 69 
A κ-PIVF        DCCGVKLEM-CHPCLCDNSCKKSGK 32 
A PIVH        DCCGVVMEE-CHKCLCNQTCKKK 45 
B2 Linear-P         QPSAENEEGKFRFFDKQ 6 
M Ile-Contryphan-P    GCVIWPWC 7 
M Contryphan-P3     CAIWTKC  3 
ND  Contryphan-P4*    CVYWRKC 1 
M ψ-PIIIE HPPCCLYGKCRRYPGCSSASCCQR 27 
M PIIIG QWGCCPVNACRSCHCC 2 
M PIIIH    KCCPLTACKLGSGCKCCE 7 
M PIIII    CCQA-YCSRYHCLPCC 1 
O1 δ-PVIA      EACYAPGTFCGIKPGLCCSEFCLPGVCFG 3 
O1 PVIB        QCTPYGGSCGVD-STCCGRCNVPRNKCE 67 
O1 PVIC       EACYAPGTFCGIKPGLCCSALCLPAVCID ND 
O1 PVID**       PCKKSGRKCFPHQKDCCGRACIITICP 3 
O1 PVIE   VGEFRGCAHINQACNPP-QCCRGYTCQSSYIPSCQL 16 
ND PVIF**  ATSNRPCKKTGRKCFPHQKDCCGRACIITICP 3 
O1 PVIG** GATSNRPCKIPGRKCFPHQKDCCGRACIITICP 16 
O1 κ-PVIIA        CRIPNQKCFQHLDDCCSRKCNRFNKCV 18 
O2 Contryphan-P   GCPWDPWC 1 
O3 PIIA        CCCIRSDGPKCSRKCLSSFFC 2 
S PVIIIA  GCSGSPCFKNKTCRDECICGGLSNCWCGYGGSRGCKCTCRE 33 
T PVA   GCCPKQMRCCTL 2 
T PVB    DCCPEKMWCCPL 11 





Table 5 Conopeptides identified from the injected venom of Conus 
purpurascens. Conopeptides reported for the first time here are in bold. Sequence 
alignment was performed manually for each cysteine framework. *Conopeptides 
identified with the PEAKS de novo software. **These base conopeptides were 
previously described from cDNA libraries as P2B-D [1]; since these designations do 
not conform with current nomenclature they were renamed accordingly. The number 
of toxiforms only includes peptides identified with the full cysteine framework. ND = 
not determined because there were no spectral matches associated with the 
complete base peptide. 
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Table 6- Protein sequences of identified conopeptides. Sequences were translated from RNA-seq transcripts from venom duct 
transcriptomes A (unshaded) and B (shaded). Mature peptides, as determined by MS/MS, are in bold. 
 
Superfamily Conopeptide Transcript 
A PIC MGMRMMFIVFLLVVLATTVGSFTLDRVLGLASEGRNAEAIDNALDQRDPKRRTSGCCKHPACGKNRC 
 PID MGMRMMFIVFLLVVLATTVVSFTLDRASDGRDAAANDKASDLIALTARRDPCCSNPACNVNNPQICG 
 PIVA MGMRMMFIVFLLVVLATTVVSFTSDRASDDRNTNDKASRLLSHVVRGCCGSYPNAACHPCSCKDRPSYCGQGR  
    MGMRMMFIVFLLVVLATTVGSFTSDRASDDRNTNDKASRLLSHVVRGCCGSYPNAACHPCSCKDRPSYCGQGR  
  PIVE MGMRMMFIVFLLVALATTVGSFTSDRASDGRNAAVNDKASHLIDNVIRDCCGVKLEMCHPCLCDNSCKNYGKGKKEYGK  
 PIVH                                  VVLATTVVSFTSDRASDGRNAAVNDKASPLIAKVIRDCCGVVMEECHKCLCNQTCKKKGKKELWEMMTATDKRNT 
B2 B2 linear  MLRLIIAAVLASACLAFPERRDGVPAEQANLQGFDPAAQAMPAMAGMQQMPGMAGGQFLPFNPNFGMAYKRDMDESLEKRKQHSQFNADNESPFEAGDNLGDFM
NFMKGNGNNVPFANMDSDATDLGNFQPSAENEEGKFRFFDKQQ  
    MLRLIIAAVLASACLAFPERRDGVPAEQANLQGFDPAAQAMPAMAGMQQMPGMAGGQFLPFNPNFGMAYKRDMDEILEKRKQHSQFNADNESPFEAGDNLGDFM
NFMKGNGNNVPFANMDSDATDLGNFQPSAENEEGKFRFFDKQQ 
 M Ile-Contryphan-P  MLKMGVLLFTFLVLFPLATLQLDADQPVERYVEKKQDLNPDERTKTLHALRPPSVDKRATSLGCVIWPWC 
  Contryphan P3 MLKMGVLLFIFLVLLPLATLQLDADQPVERYAENKQDLKPDERREIILPALGPPSVDKRATSLACAIWTKC  
 PIIIE  MMSKLGALLTICLLLFPITALLMDGDQPADRPAERMEDDISSEVHRLLERRHPPCCLYGKCRRYPGCSSASCCQRG  
   MMSKLGALLTICLLLFPITALLMDGDQPADRPAERMEDDISSEVHRLLERRHPPCCLYGKCRRYPGCSSASCCQRG  
 PIIIG                                      LITLQLDADQPVERYAEDKQDLNPNERMGFILPALRQWGCCPVNACRSCHCCGRSTSVALCWADSTATAVVDHVYYRAHVSCLRMTN 
  PIIIH MLKMGVLLFTFLVLFPLATLQLDADQPVERYAENKQDLKPDERREIILPALGQRKCCPLTACKLGSGCKCCE  
 PIIII MMFKLGVLLTICLLLVPLTAIPLDGDQPVDQPAERMEDGKSTPNHPWFDPVKRCCQAYCSRYHCLPCC 
O1 PVIA MKLTCVMIVAVLFLTAWTFVTADDSKNGLENHFWKARDEMKNREASKLDKKEACYAPGTFCGIKPGLCCSEFCLPGVCFGG  
    MKLTCVMIVAVLFLTAWTFVTADDSKNGLENHFWKARDEMKNREASKLDKKEACYAPGTFCGIKPGLCCSEFCLPGVCFGG  
  PVIB MKLTCVVIVAVLFLTACQLITADDSRRTQKHRALRSTTKLSMLTRQCTPYGGSCGVDSTCCGRCNVPRNKCE  
  PVIC MKLTCVMIVAVLFLTAWTFVTADDSKNGLENHFWKARDEMKNREASKLDKKEACYAPGTFCGIKPGLCCSALCLPAVCIDG  
  PVID (P2b) MKLTCVVIVAVLFLTACQLITADDSRRTQKHRALRSTTKRARSNRPCKKSGRKCFPHQKDCCGRACIITICP   
PVIE MKLTCVLIIAVLFLTACQLITAGYSRDKQVYRAVRLGDKMLRVGEFRGCAHINQACNPPQCCRGYTCQSSYIPSCQL  
PVIG MKLTCVVIVAVLFLTACQLITADDSRRTQKHRALRSTTKGATSNRPCKIPGRKCFPHQKDCCGRACIITICP  
PVIIA MKLTCVVIVAVLFLTACQLITADDSRRTQKHRALRSTTKLSLSTRCRIPNQKCFQHLDDCCSRKCNRFNKCV  
    MKLTCVVIVAVLFLTACQLITADDSRRTQKHRALRSTTKLSLSTRCRIPNQKCFQHLDDCCSRKCNRFNKCV  
O2 Contryphan-P MGKLTILLLVAAVLLSTQVMVQGDGDQPAYRNAAPRDDNPGGAIGKFMNVLRRSGCPWDPWCG 
O3 PIIA MSRFGIMVLTFLLLVSMATSHRYARGKQATRRNAINIRRRSTPKTEACEEVCELEEKHCCCIRSDGPKCSRKCLSSFFC 
S PVIIIA MMSKMGAMFVLLLLFTLASSQQEGDVQARKTRLTRDFYRTLPVSTRGCSGSPCFKNKTCRDECICGGLSNCWCGYGGSRGCKCTCRE  
    MMSKMGAMFVLLLLFTLASSQQEGDVQARKTRLTRDFYRTLPVSTRGCSGSPCFKNKTCRDECICGGLSNCWCGYGGSRGCKCTCRE  
T PVA MRCLPVFVILLLLIASAPSVDAHPKTKDDMPLASFHDNAKGTLQRLWKKRGCCPKQMRCCTLG 
  PVB MHCLPVFVILLLLIPSAPCVDAHPKTKDDMPLASFHDNAKRTLQRFWKKRDCCPEKMWCCPLG  
    MRCLPVFVILLLLIASAPSVDAHPKTKDDMPLASFHDNAKRTLQRFWKKRDCCPEKMWCCPLG 




 Figure 7- Conopeptide IDs for 27 C. purpurascens injected venom samples. 
 
Figure 8- Conopeptide frequency in injected venom of C. purpurascens. N= 27 
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3.2.2 Intraspecific venom comparison 
Hierarchal cluster analysis was employed to compare the venom profiles based on the 
total ion intensity of each base peptide (Methods Section 2.6). Total ion chromatograms 
(TIC) of injected venom (Appendix B) and conopeptide profiles varied among the 27 
samples. Two groups were distinguished from cluster analysis of the 33 base 
conopeptides, specimens 1-7, and 8-27 (Figure 9). Clustering along the y-axis 
distinguished two groups of conopeptides that correlate to different venom compositions. 
The first cluster (snails 1-7) is mainly comprised of δ- and κ-conotoxins that target the 
sodium and potassium channels, respectively. These conotoxins make up the ‘lightning 
strike’ cabal that rapidly immobilizes prey by acting on ion channels. The second cluster 
(snails 8-27) contains ψ- and α- conotoxins that both act on nAChRs and make up the 
‘motor cabal’. Principal Component Analysis supported this dual expression pattern in the 
venom and clustered samples into two distinct groups of specimens 1-6 and specimens 
8-26, with specimens 7 and 27 as outliers (Figure 10A). An overlay of chromatograms 
from specimen 5 from cluster 1 (blue) with specimen 14 from cluster 2 (red) emphasizes 
the distinction in venom profile components between the two clusters (Figure 10B). 
The conopeptide identifications were made from venom gland transcriptome 
databases of two C. purpurascens specimens (transcriptomes A and B). These specimens 
correspond to specimen venom samples 1 (snail sacrificed for transcriptome A) and 14 
(snail sacrificed for transcriptome B). To assess the coverage of the milked venom sample 
by the corresponding transcriptome, we compared conopeptide expression between these 
two specimens (Table 7). Our comparison examines the expression of each peptide 
between the two specimens at both transcriptomic (TPM) and proteomic (relative intensity) 
levels. Conopeptides expressed in the venom gland but not identified in the injected 
venom sample are shown in grey. Conopeptides identified in injected venom sample, but 
not expressed in venom gland transcriptome are shown in blue. Overall, we see a 
32 
differential expression pattern between the two specimens and between transcriptomic 
and proteomic expression within the same specimen.  
Figure 9- Conopeptide profiles from 27 C. purpurascens specimens. Ion intensities 
were normalized to the highest value for each specimen and ln(x + 1)-transformed. 
Clusters were determined by hierarchal cluster analysis using correlation distance and 
average linkage.  
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Figure 10- C. purpurascens expresses two distinct venom profiles. A) PCA analysis of normalized ion intensity for all 
conopeptide IDs (n= 27). B) Total Ion Chromatogram (TIC) overlay of Specimen 14 from cluster 1 (blue) and specimen 1 
from cluster 2 (red). 
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 Specimen 1 Specimen 14 








A α-PIA 0.00 0.00 0.00 0.00 
A α-PIB 0.00 0.00 0.00 0.00 
A α-PIC 6657.49 0.00 1214.88 0.00 
A PID  139.43 0.00 0.00 67.16 
A PIE 25.81 0.00 50.15 0.00 
A PIF  0.00 0.00 0.00 0.00 
A PIG 0.00 0.00 0.00 0.00 
A α-PIVA 8002.60 0.00 7115.58 1000.00 
A κ-PIVE 0.00 0.00 1043.68 0.22 
A κ-PIVF 0.00 989.76 0.00 0.00 
A PIVH 3962.08 1000.00 0.00 0.00 
B2 Linear-P  7081.46 0.00 2802.38 0.00 
M Ile-Contryphan-P  1985.81 1.23 0.00 0.38 
M Contryphan-P3  0.00 0.00 512.22 0.87 
? Contryphan-P4 0.00 1.29 0.00 0.00 
M ψ-PIIIE 1926.10 0.00 770.99 186.94 
M PIIIG 6.84 0.00 0.00 0.00 
M PIIIH  0.00 0.00 2988.25 97.70 
M PIIII 0.00 0.02 8.32 0.00 
O1 δ-PVIA 2642.86 13.74 3651.60 0.00 
O1 PVIB  0.00 58.13 257.39 0.75 
O1 PVIC  632.78 14.82 0.00 0.00 
O1 PVID  363.92 3.02 0.00 0.00 
O1 PVIE  0.00 0.00 152.04 0.01 
? PVIF 0.00 0.00 0.00 0.00 
O1 PVIG 0.00 0.00 569.10 0.00 
O1 κ-PVIIA 934.23 935.37 1387.09 21.09 
O2 Contryphan-P 57382.30 0.00 4647.95 0.00 
O3 PIIA 22.33 0.00 0.00 0.00 
S PVIIIA  4082.19 0.00 1193.34 74.22 
T PVA 340.10 0.00 0.00 2.68 




0.00 0.00 71.93 4.46 
  
Table 7- Comparison of transcriptome expression and MS identification from 
two specimens of C. purpurascens (Specimen 1-Transcriptome A, Specimen 14- 
Transcriptome B). Differential patterns of expression are shown by shading. 
Conopeptides expressed in the venom duct but not identified in the injected venom 
sample are shown in grey. Conopeptides identified in injected venom sample, but not 
expressed in venom duct transcriptome are shown in blue. 
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3.2.3 Novel S-superfamily conotoxin- PVIIIA 
PVIIIA is one of the 21 newly identified conopeptides and is the first member of the S-
superfamily found in injected venom. The peptide has five disulfide bonds and exhibits 
cystine framework VIII (C-C-C-CXaaC-CXaaC-CXaaCXaaC). It was expressed in high 
frequency and abundance within this C. purpurascens population. It was identified in 23 
of the 27 venom samples (Figure 8). When venom profiles were compared, PVIIIA 
expression clustered closely with α-PIVA and ψ-PIIIE, which both target nicotinic receptors 
as part of the motor cabal (Figure 9). Alignment with functionally characterized S-
superfamily conotoxins, known to target serotonin (σ-GVIIIA) and nicotinic (α-GVIIIB, α-
RVIIIA) receptors, exhibits very little sequence homology aside from the conserved 
cysteine framework (Figure 11). PVIIIA is 41 residues in length and has 5 sites of 
modification, as determined by MS/MS spectral matching. We mapped all identified PTMs 
for the 33 toxiforms of PVIIIA (Appendix A). The following sites of modification were 
determined: oxidated Pro(6), carboxylated Glu(16), deamidated Asn(10, 24), and 
truncations on both N- and C- terminals. These modifications occur in most possible 
combinations, significantly expanding the molecular diversity of the PVIIIA base peptide. 
We also compared toxiform expression among the 27 specimen samples (Figure 12). The 
heatmap shows two clusters of peptides, which correlate to high abundance (top cluster) 
and lower abundance (bottom cluster). The six toxiforms in the top cluster exhibit the 
highest expression within the samples, as shown by color, and also within the population 
  
Figure 11- Alignment of PVIIIA with characterized S-superfamily conotoxins 
σ-GVIIIA, α-RVIIIA and α-GVIIIB. Cysteines are highlighted in yellow to 





3.3  Discussion 
Proteogenomic approaches, including functional genomics (transcriptomics), are 
ideally suited to study venom. The proteinaceous nature of venom allows a 
comprehensive assessment of the venom composition (venome) and the study of venom 
dynamics (venomics). Here, we have applied venomics to study the intraspecific variability 
of the injected predatory venom used by C. purpurascens, a fish-hunting cone snail that 
has been studied intensively for the past 25 years [113, 114]. Studies on cone snail venom 
Figure 12- PVIIIA toxiform expression from 27 C. purpurascens specimens. Total 
ion intensities were calculated for each toxiform. Ion intensities were normalized to the 
highest value for each specimen and ln(x + 1)-transformed. Rows and columns are 
clustered using correlation distance and average linkage. 
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are quite significant, as the venom is a valuable source of bioactive peptides that can be 
used as neuronal probes and developed as novel therapeutic agents. Several 
conopeptides have reached clinical trials, including the approval of PrialtTM, among the 
most powerful painkillers known [18].  
Analysis of the intrinsic complexity of cone snail venom has been significantly 
advanced with the advent of NGS transcriptomic data that provides thousands of novel 
putative conopeptide sequences-- a trend that will continue to expand. It is critical to probe 
venom using proteomic approaches, as transcriptomic data on its own can only provide 
putative sequences. Large scale top-down proteomics/peptidomics is the best way to 
assess de facto PTMs and cleavage sites to generate mature conopeptides. We sought 
to maximize venom coverage through conopeptide identifications; however, practical 
aspects of these workflows, such as the number of available transcriptomes, size of the 
conopeptides suitable for “top-down”/enzyme-free methods, and unforeseen PTMs, may 
have an effect on the final coverage of components obtained. While recognizing these 
limitations for complete venom coverage, we were able to increase component 
identification by including sequences discovered through de novo methods and 
sequences previously reported for C. purpurascens to our search database. Regardless 
of the total coverage obtained, our results reveal a clear picture of the venom profiles and 
envenomation strategies employed by C. purpurascens.   
We show through a functional proteogenomic comparison between specimens 1 and 
14 that transcriptomic data from the venom gland does not provide complete coverage of 
the venom components. We identified conopeptides in the injected venom that were not 
represented at the transcript level, demonstrating the lack of homogeneity between the 
venom gland transcriptome and the injected venom. Of the 17 conopeptides reported in 
UniProt for C. purpurascens, 7 were not found in either venom gland transcriptome (α-
PIA, α-PIB, μ-PIIIA, ψ-PIIIF, κ-PIVF, p21a, conantokin-P, and Leu-contryphan-P). By 
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combining transcriptomes from two specimens into a search database, we were able to 
increase our total proteome coverage of the venom. However, these results emphasize 
that a transcriptome is a snapshot of gene expression at the precise moment the animal 
was sacrificed for mRNA extraction and cannot be used alone to fully describe the 
dynamics of venom expression. Other limitations include missing toxin transcripts during 
the transcriptome assembly process, as de novo assemblers can face difficulties when 
attempting to process large numbers of closely related transcript isoforms [115]. 
We aimed to achieve high-confidence peptide identifications to help describe the 
molecular mechanisms of predations utilized by this population of C. purpurascens. Our 
venomics approaches led to the identification of 543 conopeptides, which are the result of 
33 base sequences and their corresponding toxiforms, significantly expanding the current 
inventory of C. purpurascens conopeptides. As expected, these are only a fraction of the 
putative conopeptide base sequences predicted by transcriptomic expression or by the 
number of unique masses deconvoluted at the MS1 level [89]. We were able to ascertain 
numerous toxiforms from the 33 identified base conopeptide sequences. Cone snails have 
the remarkable ability to engineer their venom peptides through hyper-modification, a 
molecular adaptation to hunting strategy [22, 103, 104]. These PTMs may have important 
implications for the development and molecular engineering of novel peptide-based 
therapeutics [116-118]. Using spectral matching we were able to detect sites of differential 
hydroxylation and carboxylation, which could not be deciphered through mass matching 
alone.  
Our results emphasize the importance of identifying venom components from the 
injected venom, the actual brew delivered into prey. This is in striking contrast to 
intraspecific studies that utilized dissected venom [85, 119], which neglect venom 
processing and delivery at several levels. This is the first study using high-resolution mass 
spectrometry, transcriptomic data and de novo approaches on the injected venom of a 
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large group of individuals of the same species for the global identification of components, 
assessment of venom dynamics, and evaluation of synergistic interactions between 
conopeptides and their potential pharmacology.  
The conopeptide composition of the predatory injected venom arsenal of C. 
purpurascens consists of cysteine-constrained peptides that range from 1 disulfide bond 
(contryphans) to 5 disulfide bonds (PVIIIA and p21b). The outlier is the linear peptide 
(Linear-P) belonging to the B2-superfamily. The molecular masses ranged from 938 Da 
(Contryphan-P3) to 4960 Da (PVIIIA), indicating a wide spread of molecular features of 
these venom components. These venomes are covered by conotoxin frameworks I-VIII, 
X, and 21. Except for frameworks II, VIII, and 21, 3D structural information exists to help 
assign disulfide bonding and folding patterns [120-123] to these newly discovered C. 
purpurascens conotoxins. This is particularly true for the well-studied α-conotoxins 
(framework I) and κ-, δ-conotoxins (frameworks VI, VII). Structural assignments of the 
more complex frameworks, such as those found in PVIIIA and p21b (5 disulfide bonds), 
remain a challenge. While the structural and even functional features of novel base 
sequences can be predicted by homologies, such as PID, PIE, PIF (which are homologs 
of other well-characterized α-conotoxins), others such as PIIA, PIIIG-I, PVIE, and PVIIIA 
have no significant homology to functionally characterized conotoxins; and therefore their 
activity and role in the envenomation strategy will require further investigation.   
Hierarchical cluster analysis of the venom profiles of 27 specimens enabled us to 
ascertain strong linkages and possible synergisms between specific conopeptides through 
co-expression patterns. We found two distinct clustering patterns indicating that two 
different venom cabal combinations can be employed by C. purpurascens as a hunting 
strategy. Cluster 1 contains classical members of the lightning strike cabal, affecting 
neuronal transmission by disrupting the propagation of action potentials (δ-PVIA, κ-PVIIA, 
κ-PIVE), but not apparent members of the motor cabal, comprising paralytic toxins acting 
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primarily on nicotinic muscular targets (α or αA conotoxins). These findings provide a 
significant revision to the original venom cabal configurations for C. purpurascens. The 
original cabal concept was introduced by the synergy of conotoxins -PVIIA and -PVIA 
(the lockjaw peptide) found in the pooled venom from several individuals of C. 
purpurascens collected in the Gulf of California [111, 113]. However, when using pooled 
venom, the lightning strike cabal would be complemented with members of the motor 
cabal that includes several inhibitors of nAChRs such as a A (PIVE, PIVF, PIVG) and 
ψM (PIII-I) conotoxins, which is not the case for individuals within cluster 1 (non-pooled 
samples). Since conotoxins PIVE, -PVIIA, -PVIA, and their respective toxiforms, and 
novel conotoxins, PIVH, PVIB, PVIC, PVID (and toxiforms), are part of cluster 1, the latter 
appear to complement the lighting strike cabal within those C. purpurascens individuals.  
Cluster 2 contains several inhibitors of nAChRs such as -PIA-F, A-PIVA, and ψ-
PIIIE conotoxins in addition to components of the lighting strike cabal, δ-PVIB and κ-PVIIA 
(also present in cluster 1). This is an indication of the use of multiple cabals as the primary 
arsenal of this population of C. purpurascens. The role of PVIIIA is intriguing, as it is highly 
expressed in cluster 2, but given the abundance of nicotinic inhibitors already present 
there, it would be unlikely that another more complex nicotinic inhibitor is necessary to 
complete the motor cabal. Another curious finding within cluster 1 was the presence of 
mini-M conotoxins PIIIG, PIIIH, and PIII-I. While these conotoxins are prevalent in worm 
and mollusk-hunting Conus species [124, 125], they have not been found in the injected 
venom of fish hunting species until now. The significance of this finding is under 
investigation.  
We use PVIIIA as an example to demonstrate toxiform variability among the 27 venom 
samples. A heatmap of PVIIIA toxiforms shows two clusters of peptides (Fig. 6), high 
abundance (top cluster) and lower abundance (bottom cluster). While the toxiform 
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comparison does not provide insight into its role in the venom, it can help distinguish which 
toxiforms are most abundant within the population and provide leads for downstream 
bioactivity assays.   
Populations of cone snails in different habitats and geographical locations can show 
different venom phenotypes, as seen in C. purpurascens venom studies carried out on 
animals from the Gulf of California [111], The Clipperton atoll [126], Ecuador [127], 
Panama [83] and Costa Rica [90] showing profound differences in venom profiles. For 
example, p21a, a conotoxin with the putative ability to modulate AMPA receptors, was 
found in a C. purpurascens specimen from Ecuador [127], but not in the animals from 
Costa Rica here studied. However, the homologous conotoxin p21b was found as part of 
cluster 2, but not cluster 1. Given the differences in cabals between clusters 1 and 2, it is 
likely that p21b participates in the lightning strike cabal within cluster 2 instead of PVIA, 
which is absent in this cluster. Habitat is critical to these slow-moving creatures as they 
must adapt to very localized areas. Part of this adaptation process will be venom 
production to capture prey that is prevalent to these microhabitats. Accordingly, venom 
profiles that we found might be a product of such an adaptation. This adaption appears to 
be imprinted over their development in the wild, as upon captivity, the venom remains 
invariant as these animals were fed and kept under identical conditions.  
Despite extensive studies on C. purpurascens through decades, using HR-MS/MS 
spectral matching, we have revealed a deeper coverage of the components of the injected 
venom from 27 specimens of C. purpurascens. Furthermore, we have shown the dramatic 
venom variations from specimen to specimen and the dynamic interaction of components 
as revealed by two patterns of synergism. These findings further develop the cabal 
concept in several ways. 1) The expanded reach of components due to the hyper-
modification to generate a plethora of toxiforms, 2) novel components belonging to distinct 
cabals, and 3) the possibility of multiple cabals operating independently within the same 
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geographical group of individuals. In addition to providing the strongest evidence of venom 
cabals to date, these findings will allow us to predict molecular targets of uncharacterized 
conopeptides based on global expression patterns. These analyses will tremendously aid 
the convoluted process of developing conotoxins/conopeptides into valuable molecular 

























4.1  Introduction 
Insulin and insulin-like peptides (ILPs) belong to a superfamily of 6-9 kDa hormone 
peptides that are involved in growth and metabolism. ILP gene sequences encode signal 
peptides followed consecutively by B-chain, C-chain, and A-chain peptides. The protein is 
proteolytically processed into its active form containing A-and B-chain peptides connected 
by two disulfides [128]. Human insulin has provided critical information on the structure 
and function of the insulin scaffold, including the key amino acid residues needed for 
insulin dimerization and receptor binding [129-131]. These findings enabled the production 
of human recombinant insulin therapy, Humulin [132], and its fast-acting analog, Humalog, 
or insulin lispro [133]. The commercialization of insulin has significantly prolonged the 
lifespan and improved the quality of life for hundreds of millions of diabetics worldwide 
[134]. 
The insulin superfamily is a diverse group of hormone peptides that are found 
throughout animal phylogenies, from unicellular organisms to the most complex 
vertebrates [135]. In vertebrates, the superfamily includes insulin, insulin-like growth 
factors (IGF-1 and IGF-2), and relaxin, which are involved in glucose metabolism, growth, 
and pregnancy, respectively. Invertebrates have greatly expanded the function of the 
insulin superfamily through a diversity of ILPs. Unlike their vertebrate counterparts, 
invertebrate ILPs are the products of multi-gene families. This gene expansion is reflected 
through tissue heterogeneity and the multi-faceted physiological role of ILPs within 
invertebrate systems [136-139]. Examples of well-studied invertebrate ILPs include the 
insect bombyxins [140], molluscan insulin-like peptides (MIPs) [141, 142], and Drosophila 
insulin-like peptides (DILPs) [143]. Invertebrate ILPs are involved not only in carbohydrate 
metabolism and growth, but also in reproduction, diapause, aging, and immunity [144].  
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Gene diversification has led to the incorporation of endogenous peptide hormones into 
animal venom as an evolutionary tactic to disrupt the normal endocrine function in the prey 
[145, 146]. Because venom peptide hormones mimic endogenous hormones, they are 
promising candidates for drug development. For example, the glucagon-like peptide, 
exenatide, from the Gila monster saliva, mimics the exogenous hormone incretin that 
helps increase insulin release after a meal and it was developed into ByettaTM, a drug used 
for the management of Type II-diabetes [147]. 
The first record of an insulin-like peptide (ILPs) from animal venom came from Conus 
geographus (Con-Ins G1), a fish-hunting cone snail species from the Indo-Pacific region 
[148]. Cone snail venom is a complex mixture of peptides, proteins, and small molecules 
that contains several classes of hormone-like peptides, such as conopressins 
(oxytocin/vasopressin analogs) [149], conoCAPS (crustacean cardioactive peptide-like 
peptides) [150], and RFamides [151]. Proteomic analysis of C. geographus venom 
revealed a peptide resembling fish-like insulin that when synthesized and tested, 
decreased blood glucose in feeder fish, causing rapid immobilization. Since then, 
transcriptomic data from venom ducts have revealed a diversity of ILPs from across the 
Conus genus. Some Conus species use ‘weaponized-insulin’ in their venom that more 
closely resemble vertebrate insulin than MIPs [152]. These vertebrate-like insulins lack an 
extra cysteine pair that is found in MIPs. Con-Ins G1 shows modest activity against the 
human insulin receptor, despite low homology to human insulin [153]. Conoinsulins from 
other fish-hunting species, C. tulipa and C. kinoshitai, also bind and activate the human 
insulin receptor [154]. Conoinsulins also contain unique post-translational modifications 
(i.e., carboxylated glutamic acid) that may enhance their ability to bind and activate the 
insulin receptor, as suggested by increased receptor binding activity of Con-Ins G1 as 
compared to the PTM-free peptide [153].   
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The functionality of conoinsulins at the human insulin receptor has opened the door 
for screening these venom ILPs as pharmacological agents. Recently, Con-Ins G1 has 
been used as a scaffold for developing a minimized human insulin peptides (mini-Ins) 
[155]. Mini-Ins is a truncated monomeric insulin peptide that binds and activates the insulin 
receptor with comparable potency to human insulin. Using Con-Ins G1 as a model, 
alternative binding mechanisms were determined that allowed for engineering minimized 
yet fully functional human insulin peptides. 
Here, we describe a new conoinsulin (Con-Ins P1) found in the injected venom of C. 
purpurascens, a fish-hunting cone snail that inhabits the tropical Eastern Pacific region. 
C. purpurascens venom is well-studied and is known to contain conotoxins targeting 
sodium channels [113, 156], potassium channels [157], nicotinic acetylcholine receptors 
[158-161], as well as enzymes such as hyaluronidases [162], ACE, ECE [163] and 
conodipines [114]. Con-Ins P1 differs considerably in sequence and arrangement from 
other conoinsulins as it has a not truncated B chain. It is the first discovery of a hormone-
like peptide from C. purpurascens venom, and the first direct evidence of conoinsulins 
being used in injected venom for prey capture.  
4.2  Results 
4.2.1 Phylogenetic analysis of ILP expression 
Insulin superfamily proteins were compiled from the InterPro database (IPR036438). 
The InterPro database contained a total of 5,000 entries for the insulin superfamily (258 
reviewed), which included 942 unique taxa (123 reviewed). When considering reviewed 
entries alone, 85% of them are from chordates, and ~50% of these are from mammals 
(Figure 13). Invertebrate taxa include gastropods, insects, echinoderms (starfish), and 
nematode species. Gastropod taxa comprise ~10% of the InterPro insulin superfamily 
database; 65 entries from 31 Conus species and 2 entries from the venomous turrid sea 
snail, Unedogemmula bisaya (Tax ID: 746885). The reviewed proteins include 28 entries 
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from gastropods; 22 entries from cone snails and the remainder from model species 
Aplysia californica (Tax ID: 6500) and Lymnaea stagnalis (Tax ID: 6523) (Appendix D).  
Within the unreviewed Conus entries, 13 sequences exhibit the cysteine framework of 
vertebrate-like insulins rather than MIPs (Figure 14). These vertebrate-like insulins come 
from C. kinoshitai (2), C. geographus (6), C. tulipa (4), and C. lenavati (1). All the above 
are fish-hunt ing species except for C. lenavati, which is a worm-hunter.  
 
 
Figure 13- Phylogenetic tree of the insulin superfamily. 





Figure 14- Conoinsulins that exhibit a vertebrate-like insulin cysteine framework Sequences 






Figure 15- Conoinsulin sequences expressed in C. purpurascens tissue. 
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4.2.2 ILP expression in C. purpurascens tissues 
Transcriptomes from six different C. purpurascens tissue types were analyzed for ILP 
expression: venom duct, venom bulb, proboscis, eye, liver, and foot. In total, 4 transcripts 
encoding ILPs were identified (Figure 15). The transcripts exhibit heterologous expression 
among the different tissue types (Table 9). Con-Ins P1 is the most ubiquitously expressed 
in all tissue types, aside from the liver or foot where no ILP expression was found. Con-
Ins P1 has the highest expression in the venom duct (866 TPM) and the venom bulb (143 
TPM). P1 expression is significantly lower in the eye (12 TPM) and proboscis (9 TPM). 
Con-Ins P2 was also expressed in the venom duct (89 TPM); however, this protein was 
not identified through MS/MS analysis of the milked venom. Con-Ins P3 was expressed in 
low quantities (1-3 TPM) in the venom duct, bulb, and eye, and Con-Ins P4 was expressed 
only in the eye (2 TPM). 
Con-Ins P1 exhibits a cysteine framework more like vertebrate insulins than 
molluscan-type insulins. When comparing the A and B chain peptides between the four 
transcripts, Con-Ins P1 has one less cysteine residue in each, resulting in one less inter-
peptide bond. Con-Ins P1 shares a cysteine framework with other venom insulins from 
fish-hunting cone snail species (Figure 14). Con-Ins P3 and P4 are homologous to other 
MIPs, exhibiting an 8-cysteine framework. Interestingly, Con-Ins P2, also expressed in the 
venom duct, exhibits a hybrid sequence. It has an identical A chain peptide to Con-Ins P1, 
but its B chain is more like molluscan-type insulins Con-Ins P3 and P4.  
RNA expression 
(TPM) 
Con-Ins P1 Con-Ins P2 Con-Ins P3 Con-Ins P4 
Venom Duct 866.51 89.02 3.36 0 
Venom Bulb 143.13 0 2.51 0 
Eye 12.34 0 1.40 2.07 
Proboscis 9.12 0 0 0 
Liver 0 0 0 0 
Foot 0 0 0 0 
Table 8- RNA expression of conoinsulins in C. purpurascens tissues.  
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4.2.3 Con-Ins P1, new ILP from injected venom 
Con-Ins P1 was identified from the LC-MS/MS analysis of the injected venom from C. 
purpurascens. Of the 27 specimens examined, Con-Ins P1 was only identified in the 
venom of two snails (Figure 16). Two unique peptides were identified from the RNA 
transcript for Con-Ins P1. The A-chain contains 4 cysteines and the B-chain contains 2 
cysteines, which form two disulfide bonds to connect the peptides and one intra-peptide 
bond on the A chain (Figure 17). Both peptides have multiple PTMs (Figure 17). The A-
chain peptide contained either 1 or 2 carboxylated glutamates at E5, E15, or both. The B- 
chain was identified with or without hydroxylated proline (P15), deamidated asparagine 
(N21), and C-terminal amidation. C-terminal truncation occurred on the B chain resulting 
in peptides ending in either amidated A23 or G24.  
When compared to other vertebrate-like conoinsulins that have demonstrated activity 
at the human insulin receptor (Con-Ins K1, Con-Ins G1, Con-Ins-T1), Con-Ins P1 shows 
the most sequence homology to Con-Ins K1, and very little homology to G1 and T1, aside 
from a conserved insulin cysteine residues (Figure 18). All four conoinsulins maintain a 
carboxylated glutamate (E) residue; however, this is located at E5 in Con-Ins P1 and E4 
in the other three peptides. Con-Ins P1 has a second site of carboxylation at E15 and 
lacks the amidated C-terminal. Vertebrate insulins from human and zebrafish also contain 
2 glutamate acid residues in the A-chain, but carboxylation is only found in cone snail 
venom ILPs.  
The Con-Ins P1 B-chain peptide demonstrates even more sequence diversity between 
other Conus species and vertebrate homologs. It lacks an N-terminal tail but maintains an 
extended C-terminus that is lost in the other venom ILPs. The C-terminal extension 
contains an oxidated proline at P15, a deamidated asparagine at N21, and an amidated 
C-terminus. Interestingly, the oxidated residue at P15 occurs at the predicted site for 
insulin receptor binding, based on previous Con-Ins modeling studies [154]. Con-Ins P1 
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is unique from the other characterized conoinsulins in that it contains an extended C-
terminus, similar to human and zebrafish insulin, however, the P1 B-chain tail lacks the 
functional aromatic triplet, FFY, res ponsible for receptor recognition and dimerization. 
Figure 16- Con-Ins P1 from the injected venom of two C. purpurascens 
specimens. 
Figure 17- Con-Ins P1 modifications identified by MS/MS. PTM symbols: γ= 
carboxylated glutamic acid, O= hydroxylated proline, N= deamidated asparagine, * 





4.3  Discussion 
Con-Ins P1 from C. purpurascens is the first conoinsulin identified directly from injected 
venom. C. purpurascens hunts using a hook-and-pull strategy that allows for direct 
collection of the venom without dissecting the venom duct. Until now, proteomic evidence 
of conoinsulins in venom has been limited to Con-Ins G1 and Con-Ins G3 from the venom 
gland of C. geographus. In contrast to the hook-and-line strategy employed by C. 
purpurascens, C. geographus uses a net-hunting strategy in which the snail expel venom 
into the water through their expanded rostrum or ‘net’ to immobilize the fish, and then 
rapidly engulf their prey [112]. Because of the challenge of collecting venom through the 
net-capture strategy, the conoinsulins identified from C. geographus came from venom 
extruded from the dissected venom gland. Dissected venom is inherently more complex; 
it includes many protein-processing enzymes and extra components that do not ultimately 
end up in the true injected venom that is utilized by the snail against prey. Other vertebrate-
like conoinsulin sequences from fish-hunting species C. tulipa and C. kinoshitai were 
Figure 18- Con-Ins P1 displays cysteine framework homology to vertebrate 
insulins. Sequence comparison between Con-Ins P1, human and zebrafish 
insulin, and other previously described conoinsulins. Residues involved in 
dimerization are underlined. Homolgy to human insulin shown in blue. PTM 
symbols: γ= carboxylated glutamic acid, O= hydroxylated proline, N= deamidated 
asparagine, * = amidated C-terminal.  
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identified from RNAseq data and lacked proteomic evidence of their composition in the 
venom. For these reasons, the indication of ‘weaponized’ venom insulins remained 
unsubstantiated, despite evidence of their activity on human insulin receptors [154]. Our 
identification of Con-Ins P1 provides the first solid evidence that conoinsulin is actually 
injected into the prey, indicating that it plays a physiological role in prey capture.   
The identification of conoinsulins at the proteomic level has been limited and most of 
them have been found at the transcript level within the venom ducts. When considering 
the unreviewed InterPro insulin superfamily database, there are 13 (of 67) conoinsulin 
transcripts that exhibit a cysteine framework resembling vertebrate insulin peptides rather 
than MIPs and other invertebrate insulins. These 13 vertebrate-like conoinsulins come 
from fish-hunting species, C. geographus, C. kinoshitai, and C. tulipa, and worm-hunting 
species C. lenavati. The presence of vertebrate-like insulin in the venom duct 
transcriptome of a worm-hunter contradicts the theory that these insulins have been 
‘weaponized’ by piscivorous cone snails. If the theory of weaponized insulin holds, C. 
lenavati may be capable of a mixed hunting strategy, switching between fish and worms 
depending on what is readily available, but this is speculation. At this point, there is no 
proteomic evidence to confirm the presence of conoinsulin in the injected venom of worm-
hunting snails. Proteomic analysis of the worm and mollusk-hunting cone snails is an area 
that is not well-studied and must be investigated to better understand the function of insulin 
in the venom/duct.  
Another striking observation is the absence of vertebrate-like insulin transcripts in the 
venom ducts of other fish-hunting species (i.e. C. bullatus, C. magus, C. striatus, and C. 
ermineus). It may be that only some lineages of fish-hunters gained this alternative 
function of ILPs by incorporating it in their venom arsenal, or that others have lost this 
evolved trait. The absence of vertebrate-like conoinsulin in C. ermineus is especially 
interesting, being that it is a close relative to C. purpurascens and that the two species 
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exhibit high sequence homology and even overlap in their venom toxins (Grandal et al. 
2020, in review). From the venom mRNA data currently available, we cannot conclude 
that ‘weaponized’ insulin is unique to fish-hunting species because it is present C. leviteni, 
nor can we state that is ubiquitous in fish-hunting cone snails. Furthermore, our current 
understanding of venom conoinsulins is based on transcriptomic data of a limited sample 
size – in most cases, one or two specimens per species. In this situation, genomic, 
transcriptomic, and proteomic data are all critical to deduce how and why these venom 
conoinsulins evolved.  
Venom conoinsulins are likely the result of gene duplication and diversification. Such 
is the case with lactrodectins, neuropeptide hormone homologs recruited into the venom 
by various arthropod taxa [145, 146], and glucagon-like peptides from lizard venom [164]. 
Evidence for this in cone snails lies in the heterogeneous expression of different ILPs in 
different tissue types. This has been shown previously in the net-hunting species C. 
geographus [152], and here in the hook-and-pull hunter C. purpurascens. In both cases, 
venom conoinsulins have higher expression rates than endogenous MIPs, but this high 
expression was limited to venom duct and venom bulb tissue. Con-Ins P1 (venom insulin) 
was also expressed in the proboscis and eye tissue where its function remains in question. 
The other two conoinsulins identified from C. purpurascens (Con-Ins P3 and P4) more 
closely resemble MIPs rather than vertebrate insulins. We found that Con-Ins P3 and P4 
had much lower expression than Con-Ins P1, but the expression patterns between the two 
differed. Con-Ins P3 was expressed in the venom duct, bulb, and eye, while Con-Ins P4 
expression was limited to the eye. Con-Ins P2 resembles a hybrid ILP, its signal peptide 
and A-chain sequence show 100% homology to Con-Ins P1, while its B-chain is more 
similar to Con-Ins P3, P4, and other MIPS. Con-Ins P2 may be key to our understanding 
of conoinsulin diversification and the evolution of venom insulins from endogenous MIPs. 
Lymnaea stagnalis’ MIPs are produced and secreted by neuroendocrine glands and are 
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important for growth, metabolism, and other processes of neurodevelopment [137, 165]; 
however, their role in Conus venom is unclear. They may be part of endogenous signaling 
mechanisms, or cone snails may utilize these molluscan-type insulins in their venom to 
interrupt the cellular processes of their molluscan prey. Although we don’t know why some 
species express these vertebrate-like venom insulin peptides and others don’t, the new 
evidence of conoinsulins in injected venom supports the model of insulin weaponization 
through gene diversification.  
Con-Ins P1 is unique from all previously identified conoinsulins in that we have 
identified differential modes of PTMs determined by MS/MS spectral matching. Previously, 
the synthetic modified version of Con-Ins G1 showed more activity at the human insulin 
receptor than the PTM-free peptide [153]. Since Con-Ins P1 contains different 
modifications at different positions than G1, it will be important to assess the effect of its 
different modified forms for their ability to bind and activate the insulin receptor. It will be 
especially important to assess the effect of hydroxylated P15 residue on the C-terminus 
of Con-Ins P1 because it is located in the predicted functional site for Con-Ins activity 
based on previous molecular docking studies [154].  
Con-Ins P1 is also unique from other vertebrate-like conoinsulins in that it lacks the N-
terminal tail on the B-chain but maintains an elongated C-terminus, also found on human 
and zebrafish insulins. The C-terminus of the B-chain in human insulin includes the 
aromatic triplet, known to be critical to the binding mechanism [166]. A recently developed 
minimized insulin analog, based on the framework of Con-Ins G1, mini-Ins, maintains 
binding activity despite lacking the C-terminus region of the B-chain [155]. This, along with 
the proven activity of conoinsulins, is evidence that the aromatic triplet is not essential for 
conoinsulin function. However, since the B-chain C-terminal has significant structural 
implications for binding, Con-Ins P1 may provide insight into new mechanisms for ligand-
receptor interaction  
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Molecular docking studies for vertebrate-like conoinsulins reported six conserved 
residues within the bioactive conoinsulins: Glu4, Lys/Arg9, and Ser12 in the A-chain and 
Ser9, Glu/Asp10, and Glu/Asp17 in the B-chain [154]. Con-Ins P1 only has one of these 
six conserved residues, emphasizing its uniqueness among the vertebrate-like venom 
insulins. The one conserved residue is aspartate at site B10, consistent with both Con-Ins 
T2 and T3, while the others have glutamate, which is predicted to be carboxylated. Human 
insulin has a histidine at site B10 that is thought to be involved in receptor recognition and 
activation. Amino acid substitution studies have shown that replacing this histidine with an 
aspartate increases the peptide’s activity by 4-5 fold, presumably due to the negatively 
charged residue [167]. This mutated peptide was developed into a rapid-acting insulin 
analog but it was discontinued due to mitogenicity [168, 169]. All vertebrate-like venom 
insulins identified thus far contain a negatively charged residue (i.e. histidine) at position 
B10. Con-Ins P1, however, also maintains the following three residues (LeuB11, ValB12, 
and GluB13) that are identical to human insulin. For these reasons Con-Ins P1 makes an 
interesting case study for molecular dynamics, using Con-Ins P1 as a model. 
The discovery of vertebrate-like conoinsulins from cone snail venom has opened the 
door to the development of novel insulin analogs, like mini-Ins. The uniqueness of Con-
Ins P1 compounded by its presence in injected venom makes this peptide a prime 
candidate for drug development. The first step is to use model the molecular dynamics 
using advanced cryo-EM structures of the insulin receptor [170-172]. We can use this 
information to deduce critical residues for binding and assess the effects of individual 
PTMs, as well as single amino acid mutations. These molecular modeling studies can 
advance our current understanding of human insulin-receptor interaction and provide 
grounds for developing novel, high-efficiency insulin analogs as complementary therapies 
for hyperglycemic metabolic conditions.  
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CHAPTER 5: 
FUNCTIONAL SCREENING OF NOVEL ALPHA-CONOTOXIN ACTIVITY ON 
NICOTINIC ACETYLCHOLINE RECEPTOR SUBTYPES 
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5.1  Introduction 
Alpha-conotoxins are inhibitors of the nAChR and are the most ubiquitous venom 
components across the Conus genus; all species analyzed express one or more α-
conotoxins in their venom [100]. Unique from other nAChR ligands, α-conotoxins exhibit 
subtype selectivity, specifically among neuronal receptor subtypes [52, 55]. Selective 
ligands of nAChR subtypes are clinically important probes for studying the 
pathophysiology behind diseases like addiction, cognitive disorders, neurodegenerative 
diseases, and pain [48, 173, 174]. Subtype specificity makes α-conotoxins valuable 
molecular probes for basic neuroscience research and drug design.  
The framework I α-conotoxins belong to the A Superfamily, as defined by a conserved 
gene signal sequence. This is the largest group of characterized α-conotoxins with the 
greatest diversity in subtype selectivity. The post-translational modifications commonly 
found on these conotoxins (C-terminal amides and hydroxyprolines) are important for 
peptide stability and bioactivity [51]. Within the framework I α-conotoxins, there is 
significant diversity in amino acid composition and the size of the inter-cysteine loops. The 
size of the α-conotoxin inter-cysteine loops has been shown to affect affinity toward either 
muscular or neuronal nAChR subtypes (Figure 3) [53, 54], and can therefore be used to 
predict the target of uncharacterized toxins based on homology. In general, α-conotoxins 
exhibiting a 3/5 inter-cysteine loop pattern are inhibitors of neuromuscular junction 
subtypes, and 4/3 and 4/7 toxins inhibit neuronal subtypes [55]. 
Neuronal subtypes are expressed heterogeneously throughout the central nervous 
system [56]. The most widely expressed subtype in the mammalian brain, α4β2, is heavily 
involved in the dopaminergic pathway and nicotine addiction. This receptor can exhibit 
different subtype stoichiometry; (α4)2(β2)3 is more sensitive to nicotine than (α4)3(β2)2 [57]. 
Because of its role in nicotine addiction, α4β2 is the clinical target for smoking cessation 
therapies, including the partial agonist, varenicline (Chantix, Pfizer, Inc.). Very few α-
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conotoxins inhibit α4β2 but not exclusively, α-GID being the most potent inhibitor [58]. The 
α3β4 subtype is the predominant nAChR in the sensory and autonomic ganglia neurons 
and is expressed in the mesolimbic dopamine circuitry of the midbrain where it modulates 
addiction to nicotine and potentially other drugs of abuse [61, 62]. Only α4/6- conotoxins 
α-AuIB and α-TxID have demonstrated specificity for this subtype [63, 175]. 
The α6-containing subtypes are also expressed abundantly in the midbrain 
dopaminergic neurons and are mediators of the addiction reward pathway [65, 66, 176, 
177]. Ligands with selectivity for α6-subtype nAChRs are important molecular probes to 
study the pathophysiology of addiction and other dopamine-related disorders, such as 
Parkinson’s disease. However, α6 selectivity is rare because of its high homology with the 
α3 subunit. There is one α6-biased ligand known thus far from C. purpurascens, α-PIA, 
which preferentially inhibits α6-containing receptors with 75-fold greater affinity than α3 
receptors [67, 68]. 
Homomeric α7 nAChRs are a unique subtype expressed throughout the brain, 
including the hippocampus and cerebral cortex involved in learning and memory [71], as 
well as in non-neuronal tissues, like immune cells [70]. Along with a6 receptors, α7 
receptors are involved in nicotine reward pathways and present molecular targets for 
smoking cessation therapeutics [178-180]. The α7 subtype is also involved in pain and 
inflammation pathways [174, 181]. Ric-3 is an important assembly protein found to 
increase the assembly and expression of α7 receptors [182] and is therefore co-expressed 
with the α7 subunit in this study for functional assays. Several structure-activity studies 
with α4/7-conotoxins have identified critical residues for α7 activity [183-185].  
The ligand-binding properties of nAChRs have been studied using the X-ray crystal 
structure of the soluble acetylcholine binding protein (AChBP) of mollusks Lymnaea 
stagnalis and Aplysia californica [43, 186]. AChBPs are not functional ion channels, 
however, they form stable homopentamers that preserve features of the ligand-binding 
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domain of nAChRs, and thereby serve as useful binding models for α-conotoxins [186, 
187]. The AChBP is particularly useful for the homology modeling of the homopentameric 
α7 subtypes [160, 188]. 
There are several previously characterized α-conotoxins from the venom of C. 
purpurascens. Framework IV toxin, α-PIVA, is a paralytic nAChR antagonist selective for 
muscle-subtype receptors. It is present in the venom in differentially modified forms, 
including multiple sites of proline hydroxylation, which affects bioactivity [189]. The 
characterized framework I toxins from C. purpurascens include α-PIA, α-PIB, and α-PIC. 
Both α-PIB and α-PIC target muscle receptor subtypes [160, 190], while α-PIA is selective 
for α6 containing neuronal receptors [191].  
Here, we will focus specifically on the framework I α-conotoxins because they 1) have 
a conserved two-disulfide bonding pattern (1-3, 2-4), and 2) are relatively small peptides 
(<22 residues). These characteristics simplify solid-state peptide synthesis for functional 
assays. First, we considered α-conotoxins identified from the injected venom of C. 
purpurascens. These included α6-selective conotoxin, α-PIA, and newly identified α-PID 
(Grandal et al. 2020, in review). Both peptides exhibit a 4/7 inter-cysteine loop size and 
significant sequence homology. We also evaluated venom duct transcriptomic data from 
other Conus species for expression of α-conotoxins. Two α4/4- conotoxins, α-NuxI from 
Conus nux and α-CedI from Conus cedonulli, were also synthesized for functional 
screening. Here, we propose to test the inhibitory activity of three novel α-conotoxins, α-
PID, α-NuxIA, and α-CedIA, as well as previously described α-PIA. We predict they will be 
selective for neuronal subtypes over neuromuscular nAChRs based on their inter-cystine 
loop size.  
62 
5.2  Results: 
5.2.1 Bioinformatic approach to identifying novel α-conotoxins 
A conserved A superfamily signal sequence was used to identify putative α-conotoxin 
transcripts from the transcriptomes of 17 Conus species. The BLAST search returned a 
total of 57 transcripts, from which we predicted the mature α-conotoxins sequences 
(Figure 19). The search included some previously characterized α-conotoxins, including 
α-SI (C. striatus), α-SrIB (C. spurius), α-RgIA and α-RgIB (C. regius), and α-PIC (C. 
purpurascens). 
All the sequences share framework I cysteine pattern, CC-(X)m-C-(X)n-C. In these 
sequences, the first inter-cysteine loop (m) contained either 3 or 4 residues, while the 
second loop (n) contained either 3, 4, 5, 6, 7, or 9 resides, resulting in the following loop 
patterns: 3/5, 4/3, 4/4, 4/5, 4/6, 4/7, or 4/9. There is high sequence homology among α-
conotoxins from different species; in many cases only 1 or 2 residues are different. Six 
sequences are expressed in multiple species, including α-PIC from C. purpurascens, 




Figure 19- Sequences of α-conotoxins extracted from Conus venom duct 
RNA-seq transcripts. 
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5.2.2 Functional screening of novel α-conotoxins on nAChR subtypes 
We chose three α-conotoxins from the 57 identified sequences to have synthesized 
for functional assays: α-PID from C. purpurascens, α-NuxIA from C. nux, and α-CedIA 
from C. cedonulli. We also obtained previously characterized α-PIA from a commercial 
source as a positive control for screening assays. Both α-CedIA and α-NuxIA exhibit a 4/4/ 
loop pattern, while α-PIA and α-PID exhibit a 4/7 loop pattern (Figure 20). α-PIA and α-
PID have highly homologous sequences, with a one residue difference in the first loop and 
a two residue difference in the second loop (82% similarity). Each contains 18 residues, 
however, α-PID has a one residue N-terminal deletion and C-terminal elongation 
compared to α-PIA. α-NuxIA and α-CedIA contain 15 and 13 residues, respectively, and 
very little sequence homology aside from asparagine and proline residues in the first loop 
that are consistent across all 4 sequences (46% similarity).  
Functional screenings were performed on nAChR subtypes expressed in Xenopus 
oocyte vectors. Inhibition of ACh-induced current was measured for the following nAChR 
subtypes: human neuronal receptors β3α4β2α6β2, α7, α3β4, α4(2)β2(3), α4(3)β2(2), 
α4α5β2, and mouse muscle receptor α1β1δε (Table 4). Screening assays measured α-
CNTX (1 μM) inhibition of ACh-induced current (Figure 21). α-CNTX -elicited responses 
were normalized to ACh control currents so that inhibition values represent % control. 
All four α-conotoxins inhibit the muscle subtype mα1β1δε (Table 10); the most potent 
inhibitor at 1 μM was α-NuxIA (0.15 ± 0.01, p= 0.008) with IC50 of 47.4 nM (Figure 22). 
The other three elicited ~50% inhibition at 1 μM (Figure 21). 
Alpha-PID significantly inhibits neuronal subtypes α3β4 (0.73 ± 0.03, p= 0.001) and 
α4(2)β2(3) (0.84 ± 0.02, p= 0.006). α-CedIA also significantly inhibits α4(2)β2(3) (0.90 ± 
0.02, p= 0.005), while α-NuxIA significantly inhibits α4(3)β2(4) with alternative 
stoichiometry (0.78 ± 0.04, p= 0.002). No significant inhibition was measured on receptor 
α4α5β2. 
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Both α-PID (0.14 ± 0.02, p= 0.0003) and α-PIA (0.06 ± 0.03, p= 0.055) strongly 
inhibited the β3α4β2α6β2 receptor concatemer. These values corresponded to an 86% 
inhibition of ACh-induced current by α-PID and 94% inhibition by α-PIA. An inhibitory dose-
response curve (30 nM, 100 nM, 300 nM, and 1μM) calculated an IC50 of 119.7 nM for α-
PID and 329.9 nM for α-PIA (Figure 23A). α-PIA exhibited a greater response at higher 
concentrations (1 μM and 300 nM), while α-PID exhibited a greater response at lower 
concentrations (100 nM and 30 nM) (Table 11). The β3α4β2α6β2 receptor was also 
significantly inhibited by 1 μM α-CedIA (0.74 ± 0.02, p= 0.031), although to a lesser extent 
than α-PIA and α-PID. α-NuxIA also demonstrated minor inhibition on β3α4β2α6β2, 
although not significant (0.78 ± 0.07, p= 0.294). 
Alpha-PID also significantly inhibited α7 receptors at 1 μM (0.35 ± 0.05, p= 0.057) and 
300 nM (0.54 ± 0.05, p= 0.029) (Table 11, Figure 23B). 
 
Table 9- Inhibitory activity of Framework I α-conotoxins from C. purpurascens. 
α-CNTX Sequence Reference nAChR selectivity 
α-PIA -RDPCCSNPVCTVHNPQIC This work 
 
Dowell (2002) 
hβ3α4β2α6β2* >> mα1β1δε >> hα4(3)β2(2) > 
hα4(2)β2(3) > hα4α5β2 ≈ hα3β4 > hα7  
rα6/α3β2β3 > rα6/α3β4 > rα3β2 > rα3β4 >> rα4β2 
hα6/α3β2β3 > hα6/α3β4 >> hα1β1δε 
α-PIB QSPGCCWNPACVKNR---C Lopez-Vera (2007) mα1β1δε ≈ mα1β1δγ 
α-PIC --SGCCKHPACGKNR---C Hoggard (2017) rα1β1δε > rα1β1δγ ≈ hα3β2 >> hα7 
α-PID --DPCCSNPACNVNNPQICG this work hβ3α4β2α6β2* > hα7 > mα1β1δε > hα3β4 > 
hα4(2)β2(3) > hα4(3)β2(2) ≈ hα4α5β2 




Table 10- Inhibitory activity of α-PIA, α-PID, α-NuxIA, and α-CedIA on nAChR 
subtypes. Values represent % ACh- elicited response ±SEM (n). p-values calculated by 
a paired t-test.  
 α-PID α-PIA α-NuxIA α-CedIA 
α1β1δε 0.59 ± 0.03 (8) 
p= 0.025 
0.52 ± 0.06 (5) 
p= 0.093 
0.15 ± 0.01 (4) 
p= 0.008 
0.57 ± 0.04 (4) 
p= 0.046  
α3β4 0.73 ± 0.03 (4) 
p= 0.001 
0.96 ± 0.07 (3) 
p= 0.266 
0.90 ± 0.02 (3) 
p= 0.066 
1.16 ± 0.11 (3) 
p= 0.145 
α4(2)β2(3) 0.84 ± 0.02 (8) 
p= 0.006 
0.91 ± 0.02 (4) 
p= 0.802 
0.95 ± 0.19 (8) 
p= 0.298 
0.90 ± 0.02 (8) 
p= 0.005 
α4(3)β2(2) 0.91 ± 0.06 (4) 
p= 0.129 
0.84 ± 0.08 (4) 
p= 0.120 
0.78 ± 0.04 (4) 
p= 0.002* 
0.91 ± 0.04 (4) 
p= 0.137 
α4α5β2 0.91 ± 0.06 (4) 
p= 0.112 
0.94 ± 0.13 (3) 
p= 0.316 
0.90 ± 0.09 (4) 
p= 0.201 
0.98 ± 0.15 (4) 
p= 0.234 
α7 0.35 ± 0.05 (4) 
p= 0.057 
1.09 ± 0.18 (4) 
p= 0.380 
0.94 ± 0.10 (4) 
p= 0.257 
0.97 ± 0.19 (4) 
p= 0.336 
α4α6β2β3 0.14 ± 0.02 
(19) 
p= 0.0003 
0.06 ± 0.03 (4) 
p= 0.055 
0.78 ± 0.07 (3) 
p= 0.294 
0.74 ± 0.02 (4) 
p= 0.031 
 
Figure 21- Inhibitory activity of α-PIA, α-PID, α-NuxIA, and α-CedIA on 







Figure 23- Dose response curve for α-PIA and α-PID on α4α6β2β3 and α7 nAChRs. 
Error bars represent ± SEM 
Figure 22- Dose response curve for α-NuxIA on α1β2δε nAChRs. 
Error bars represent ± SEM 
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 α4α6β2β3 α7 
[α-CNTX] α-PID α-PIA α-PID α-PIA 
1 μM 0.14 ± 0.02 
p= 0.0003 
0.06 ± 0.03 
p= 0.055 
0.35 ± 0.05 
p= 0.057 
1.09 ± 0.18  
p= 0.380 
300 nM 0.36 ± 0.04 
p= 0.002 
0.24 ± 0.03 
p= 0.006 
0.54 ± 0.05 
p= 0.029 
0.97 ± 0.30 
p= 0.491 
100 nM 0.53 ± 0.02 
p= 0.025 
0.95 ± 0.10 
p= 0.439 
0.82 ± 0.17 
p= 0.215 
1.25 ± 0.34 
p= 0.317 







5.2.3 Modeling α-PID and α-PIA binding to the α7 nAChR 
Homology modeling was used to model the extracellular domain of the human α7 
receptor based on the structure of Aplysia AChBP bound to α-LvIA (PDB: 5XGL) [192]. By 
replacing α-LvIA with α-PIA and α-PID, we were able to model and compare their binding 
dynamics to the α7 homopentamer. The models contain five α-CNTX molecules bound 
between each adjacent subunit (Figure 25A). Each of the five bound α-CNTX was 
analyzed for contacts, in the form of hydrogen bonds, with the principal (p) and the 
complementary (c) receptor subunits (Figure 25B). All possible sites of contacts combined 
from the five bound α-CNTXs are summarized in Figure 25C. α-PID had seven residues 
in contact with the c subunit (P2, C4, S5, N10, V11, C17, and G18), three residues in 
contact with the p subunit (N6, P7, N13), and one residue with contact to both (N12). α-
Table 11- Dose-response of α-PIA and α-PIDc on α4α6β2β3 and α7 nAChRs. 
Values represent % ACh- elicited response ±SEM. p-values calculated by a paired 
t-test. 
Figure 24- Alignment of α-PID and α-PIA with conotoxins that inhibit α7 receptors. 
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PIA had four residues in contact with the c subunit (R1, D2, N7, N14), two residues in 
contact with the p subunit (S6, C18), and two residues in contact with both (T11, V12). 
Overall, α-PID showed more possible interactions (10 residues) compared to α-PIA (8 
residues). 
 
5.3  Discussion 
Alpha- conotoxins are venom peptides that selectively bind and inhibit nAChRs. Their 
role in cone snail venom is analogous to that of α-bungarotoxins in snake venom, to block 
neurotransmission at the postsynaptic membrane in the neuromuscular junction, thereby 
immobilizing prey. What sets α-conotoxins apart from other nAChR ligands is their unique 
affinity for neuronal nAChR subtypes, which are not involved in muscle movement, but 
rather are highly involved in neurotransmitter signaling processes in the brain. It is not 
known whether cone snails have evolved to target receptors homologous to vertebrate 
Figure 25- Model of α-PID bound to human α7 receptor. A) α-PID (red) bound at all 
five binding sites and B) α-PID (red) in the binding pocket between two adject α7 
subunits, the principal (p) subunit (purple) and the complimentary (c) subunit (green). 
This model used the structure of α-LvIA bound to the AChBP (PDB: 5XGL) as a 
template. C) α-PID and α-PIA residue contacts with the hα7 receptor determined by 
molecular energy and distance calculations. Contacts are color coded by the following: 
black= c subunit, red= p subunit, green= both c and p subunit contacts. 
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neuronal receptors in their invertebrate prey [193], or if the neuronal subtype specificity is 
an anomaly that happens to be to our benefit, as these neuronal subtypes contribute to 
the pathophysiology of many devastating human diseases [181].       
Neuronal nAChR subtypes include all subunit arrangements other than the muscle 
subtype, α1β1(δ/γ/ε). In this study we screened a subset of human neuronal receptor 
subtypes: β3α4β2α6β2, α7, α3β4, α4(2)β2(3), α4(3)β2(2), and α4α5β2. Alpha-conotoxin 
selectively has been broadly attributed to the inter-cysteine loop sizes of these small 
disulfide-constrained peptides. Muscle-subtype selectivity is commonly found in α3/5 
conotoxins (3 and 5 residues in the first and second inter-cysteine loops), while α4/3, α4/4, 
and α4/7 conotoxins tend to inhibit neuronal subtypes. Here, we screened two new α4/4 
conotoxins (α-NuxIA and α-CedIA) identified from RNA sequencing, and two α4/7 
conotoxins (α-PIA and α-PID) identified in the injected venom of C. purpurascens (Grandal 
et al. 2020, in review). α-PIA has been previously described as an α6-selective conotoxin 
with the unique ability to distinguish between the similar α3 and α6 subunit, (Table 9) [67]. 
We aimed to validate these previous findings and expand the functional screening to 
include α7 receptors. We predicted that all four α-conotoxins would show preferential 
inhibition toward neuronal subtypes over neuromuscular receptors, based on their inter-
cysteine loop sizes. 
The results from the screening assays showed that all four α-conotoxins did not exhibit 
selectivity for neuronal subtypes. The first notable finding from this body of work is that all 
four α-conotoxins showed inhibition of the muscle subtype, mα1β1δε, by at least 40%. It 
is well supported that α3/5 conotoxins have a high affinity for the muscle subtype of the 
nicotinic receptor [50], but we did not expect to see α1β1 inhibition by α4/7 conotoxins, 
based on previously characterized α-conotoxins [53, 54]. This is also in stark contrast to 
previous functional assays with α-PIA on hα1β1δε receptors, where 10μM (10x our 
screening concentration) α-PIA did not affect inhibition. This could be due to the 
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discrepancy in the species cDNA, as previous studies used human receptors [67], and 
here we used mouse muscle receptors. The strongest inhibition of mα1β1δε muscle 
receptors detected in this study was demonstrated by α4/4 conotoxin, α-NuxIA, (IC50= 47 
nM). Existing data on α4/4 conotoxin subtype specificity is limited; however, two α4/4 
conotoxins have been identified from C. purpurascens (α-PIB and α-PIC). Both conotoxins 
also showed high affinity for muscle α1β1δε receptors over neuronal subtypes (Table 9) 
[160, 190]. Although α-NuxIA shows little sequence homology to α-PIB or α-PIC, the 
combined evidence suggests that the α4/4 framework conotoxins, like the α3/5 
conotoxins, are selective for neuromuscular nicotinic receptors.  
The second strongest inhibition was on the α6-containing concatemer, hβ3α4β2α6β2 
by both α-PIA (329 nM) and α-PID (119 nM). At the highest concentration (1 μM) α-PIA 
shows greater inhibition than α-PID (96% vs 84%), but at lower concentrations (100 nM 
and 30 nM) α-PID has a stronger effect, resulting in a lower IC50 value than α-PIA. 
Previous studies report a much lower IC50 (1.7 nM) for α-PIA on hα6/α3β2β3 receptors 
[67]. However, we cannot make a direct comparison to these studies because we used an 
α6 concatemer in this screening study that contained α6 and α4 subunits (β3α4β2α6β2), 
while previous studies used an α6/α3 chimeric receptor. Because α6 and α3 are highly 
homologous structures, this likely explains the stronger inhibition by α-PIA, as it is much 
more selective for α6/α3 than for α4. Interestingly, both α-NuxIA and α-CedIA also 
inhibited the hβ3α4β2α6β2 receptor (~25% inhibition), although to a much lesser extent 
than α-PIA and α-PID.  
The finding that both α-PIA and α-PID conotoxins inhibited α6 receptors is not 
altogether surprising since they share 84% homology. More surprising was their drastic 
difference in affinity for the homomeric neuronal α7 receptor. α-PIA did not affect the hα7 
receptors, while α-PID exhibited strong inhibition (65% at 1μM). When comparing to other 
α4/7 conotoxins with α7 receptor activity (Figure 24), there is significant sequence 
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homology within the loops. Because the two share 82% identity, they present an excellent 
case for comparing binding dynamics on the α7 receptor. Therefore, we employed 
homology modeling to construct a human α7 model and predict molecular interactions 
between α-PIA/ α-PID in the binding domain.  
The hα7 extracellular binding domain bound to α-PIA/α-PID was modeled based on 
the structure of the AChBP bound to the conotoxin α-LvIA. The resulting models provided 
information on the molecular interactions of α-PIA and α-PID with the α7 receptor. Despite 
their sequence homology, the two conotoxins exhibit very different binding dynamics. 
Previous AChBP binding studies suggest that α-CNTX inhibitory activity is a result of 
interaction with the C loop located on the principal subunit. This was the case with the 
potent α7 blocker, α-PnIA, which upon binding locked the C loop in a resting state 
conformation rendering it unable to be activated [186]. Both the α-PIA and α-PID models 
had more interactions between the complementary subunit than the principal subunit. 
However, α-PID has three residue contacts with the principal subunit that are not present 
in the α-PIA model. These hydrogen bonds occur at positions N6, P7, and N13, and may 
be involved in α-PID inhibition of hα7. It is important to note that while α-CNTX interactions 
with the principal subunit are assumed critical for nAChR inhibition, interactions with the 
complementary subunit may also play a role. Going forward, amino acid substitution 
experiments with α-PIA and α-PID could be used to confirm the critical residues for α7 
activity.  
Alpha conotoxins have been studied for decades to examine their selective binding to 
nAChRs. These studies, however, have been primarily screens of a single α-conotoxin 
after isolation from the venom or through cDNA libraries. Here we demonstrate how 
advances in sequencing technology aid large-scale prediction of novel α-conotoxin 
sequences, allowing us to choose sequences based on amino acid composition and loop 
size to further dissect the underpinnings for nAChR subtype selectivity.   
73 
CHAPTER 6:  
CONCLUSIONS AND FUTURE DIRECTIONS 
  
74 
6. Conclusions and Future Directions 
The therapeutic application of venom peptides has been known for centuries [194]. 
The use of venom for medicinal purposes is far from a new notion, however, modern 
advances in molecular technologies have revolutionized venom studies. Natural product 
discovery, specifically natural peptide discovery, has evolved tremendously due to next-
generation sequencing. Genomic data 1) enables large-scale venom protein/peptide 
discovery and 2) allows us to study the evolution of venom genes across venomous 
phylogenies. In this body of work, we have capitalized on venomics methodologies to 
identify cone snail venom peptides with therapeutic potential. Our venomic approach 
merged transcriptomic and proteomic workflows to interrogate the venom of 17 Conus 
species, focusing on the fish-hunting cone snail, C. purpurascens.  
We used top-down, high-resolution MS/MS analysis and venom duct 
transcriptome databases to analyze the injected venom of C. purpurascens. We described 
33 conopeptides and all of their associated toxiforms. Twenty-one of these venom 
peptides (64% of the identified components) were identified here for the first time. Of these 
new conopeptides was PVIIIA, a five disulfide-bonded conotoxin that was abundant in 
85% of the injected venom samples, and therefore likely plays an important role in the 
venom. Comparison of the venom profiles across 27 specimens showed that the venom 
peptides clustered into two possible profiles with distinct molecular targets. The results 
provide insight into the probable pharmacological targets of newly identified venom 
peptides.  
We also described a new conoinsulin from the venom of C. purpurascens, Con-
Ins P1. This is the first ILP identified directly from injected venom, supporting previous 
evidence of ILP incorporation into the venom. Con-Ins P1 is unique from other 
conoinsulins in that it displays a different PTM profile and varies drastically in the C-chain 
sequence/ structure. We hypothesize that the sequence of the B chain C-terminal will 
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allow it to maintain activity at the insulin receptor but will not lend to self-association of 
Con-Ins P1 peptides, as self-association of human insulin decreases its bioactivity. Going 
forward, we will delve into the molecular dynamics and function of Con-Ins P1. First, we 
will model the Con-Ins P1 peptide using Con-Ins G1 as a template [153], then we will 
model the dimerization of Con-Ins P1 to assess the dimer stability. We will also model 
binding dynamics at the human insulin receptor to test our hypothesis. Based on modeling 
studies, we plan to synthesize the peptide in differentially modified forms for functional 
assays. 
The venomic approach employed in this study resulted in the identification of a 
diverse range of conopeptides with different cysteine frameworks and potential 
pharmacological targets (Table 1, Table 5). We decided to focus on the α-conotoxins for 
functional characterization due to their relative ease of synthesis to obtain large quantities. 
The α-conotoxin family of peptides has well-defined cystine connectivity, and the ones we 
had synthesized for this study were small (α-CedIA-13 residues, α-NuxIA-15 residues, α-
PID- 18 residues). We screened these toxins, along with commercially purchased α-PIA, 
on nAChR subtypes using a Xenopus oocyte expression system and two-electrode 
voltage clamp to measure inhibition of ACh-induced current. We found that α-NuxIA was 
a potent inhibitor of muscle subtype nAChRs (α1β1δε, IC50= 47 nM). Our results also 
supported previous work that α-PIA selectively inhibits α6 receptors. α-PID shares 82% 
identity with α-PIA and is a potent inhibitor of both α6 and α7 receptors. Neuronal α6 and 
homopentameric α7 play important roles in neurological and neurodegenerative diseases, 
as well as addiction [179, 181]. Selective ligands for specific nicotinic receptors are critical 
for dissecting the pathophysiology of individual subtypes. Using molecular homology 
modeling we set out to find the discriminating factor for α7 selectivity. α-PIA and α-PID 
binding to the hα7 receptor was modeled based on the AChBP-α-LvIA structure, allowing 
analysis of molecular interactions between bound α-CNTX and receptor. This analysis 
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revealed three α-PID residues in contact with the principal receptor subunit that may 
explain increased α-PIA selectivity toward hα7 over α-PIA. Further amino acid substitution 
functional assays are required to test the critical nature of these residue interactions.  
Scientists have historically, and will continue to look towards nature for the answer 
to medical questions. This body of work demonstrates how venomic methods 
(transcriptomics, proteomics) advance traditional natural product discovery techniques. In 
the case of cone snails, millions of years of evolution have engineered libraries of bioactive 
peptides with high selectivity for clinically important molecular targets. We have 
sequenced, assembled, and mined their genetic information to harness their venom 
evolution for our medical advantage. The tight disulfide constrained nature of many 
conopeptides, such as the cysteine knot peptides, has been shown to increase thermal 
and proteolytic stability, both important for developing successful drugs. However, there 
are obstacles and limitations when developing peptides as drugs.  
The largest obstacle we face in developing venom proteins/peptides as 
pharmaceutics is their inherent inability to cross biological membranes, such as intestinal 
walls or the blood-brain barrier. In the case of Prialt®, which requires an intrathecal pump 
for administration, we see how delivery techniques can limit the indication of a drug and 
can cause potential secondary health effects. Peptide engineering methods for increasing 
peptide permeation through biological membranes include cyclization and glycosylation 
[11, 12]. Some conopeptides are naturally glycosylated, such as the analgesic neurotensin 
analog, contulakin-G [195]. Based on this, cono-glycopeptides may make good drug 
candidates, however, these peptides are commonly linear, leaving them susceptible to 
proteolysis. Some peptide therapeutics can be successfully administered by systemic 
injection, such is the case for insulin and the venom derived diabetes drug, exenatide 
[196]. This has positive indications for future conoinsulin analogs which are currently being 
developed [155]. 
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Taken together, it could be argued that the value of venom research in drug 
discovery is in studying the molecular interactions and binding dynamics of the naturally 
engineered, highly selective ligands with clinical receptor targets. The large libraries of 
bioactive molecules provided by venomics approaches allow us to distinguish the critical 
residues and receptor interactions necessary for maximal response. Venom peptides 
thereby provide the tools to develop specific and effective mimetic drugs for a range of 
neuropathologies (i.e. pain, addiction, neurodegenerative diseases, neuroendocrine 
disorders). As we continue to understand the value of peptides and biologics as 




APPENDIX A: Toxiforms and sites of modification for each conopeptide identified 
from the injected venom of C. purpurascens 
 
Table 12- α-PIA toxiforms 
α-PIA R R D P C C S N P V C T V H N P Q I C G 
    
O 
    
O 
     




Annotated Sequence MH+ [Da] 
    CCSNPVCTVHNPQIC* 1844.77 
   PCCSNPVCTVHNPQIC* 1941.82 
   PCCSNPVCTVHNPQICG* 1998.84 
  DPCCSNPVCTVHNPQIC* 2056.84 
  DPCCSNPVCTVHNPQIC 2057.83 
  DPCCSNPVCTVHNOQIC* 2072.84 
  DPCCSNOVCTVHNPQIC* 2072.84 
  DPCCSNPVCTVHNPQICG* 2113.87 
 RDPCCSNPVCTVHNPQIC* 2212.95 
 RDPCCSNPVCTVHNPQIC 2213.93 
 RDPCCSNPVCTVHNOQIC* 2228.94 
 RDPCCSNOVCTVHNPQIC* 2228.94 
 RDPCCSNOVCTVHNPQIC 2229.92 
 RDPCCSNPVCTVHNOQIC 2229.93 
 RDPCCSNPVCTVHDOQIC* 2229.94 
 RDPCCSNPVCTVHNOqIC* 2229.94 
 RDPCCSNOVCTVHNOQIC* 2244.94 
 RDOCCSNOVCTVHNPQIC* 2244.94 
 RDPCCSNPVCTVHNPQICG* 2269.97 
 RDPCCSNPVCTVHNPQICG 2270.96 
 RDPCCSNOVCTVHNPQICG* 2285.96 
 RRDPCCSNPVCTVHNPQIC* 2369.06 
 
Table 13- α-PIB toxiforms 





     
O 





Annotated Sequence MH+ [Da] 
   GCCWNPACVKNRC* 1680.70 







Table 14- α-PIC toxiforms 
α-PIC S G C C K P A C G K N R C 
 
Annotated Sequence Thγo. MH+ [Da] 
SGCCKHPACGKNRC 1691.70 
 
Table 15- α-PID toxiforms 
PID R D P C C S N P A C N V N N P Q I C G 
   
O 
    
O 






Annotated Sequence MH+ [Da] 
   CCSNPACNVNNPQIC* 1806.71 
  PCCSNPACNVNNPQIC* 1903.77 











Table 16- PIE toxiforms 
 
N A A A K A F D L T A P T A G E G C C F N P A C A N N P N I C 
            
O 
         
O 
         
 





Table 17- PIF toxiforms 
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PIF Q E P G C C R N P A C V K H R C 
 
Z γ O 
    
D O 
      
* 
 
Annotated Sequence MH+ [Da] 
   GCCRNPACVKHRC* 1673.73 
  PGCCRNPACVKHRC* 1770.79 
  PGCCRNOACVKHRC* 1786.78 
  OGCCRNPACVKHRC* 1786.79 











Table 18- PIG toxiforms 
PIG P C C S N P V C T V H G G P Q L C 
                 
* 
 
Annotated Sequence MH+ [Da] 
 CCSNPVCTVHGGPQLC* 1844.77 
PCCSNPVCTVHGGPQLC* 1941.82 
 
Table 19- α-PIVA toxiforms 
 
G C C G S Y P N A A C H P C S C K D R P S Y C G Q G 
      
B O D 
    
O 
      
O 
  
* * E* * 
 
























 CCGSYPNAACHPCSCKDRPSYCGQ** 2891.10 
 CCGSYPNAACHOCSCKDRPSYCGQ* 2907.09 
 CCGSYONAACHPCSCKDRPSYCGQ* 2907.09 
 CCGSYPNAACHPCSCKDROSYCGQ* 2907.10 
 CCGSYPDAACHPCSCKDROSYCGQ* 2908.09 
 CCGSYONAACHOCSCKDRPSYCGQ* 2923.09 
 CCGSYPNAACHOCSCKDROSYCGQ* 2923.09 
 CCGSYODAACHOCSCKDRPSYCGQ* 2924.08 
 CCGSYPDAACHOCSCKDROSYCGQ* 2924.09 

















 CCGSYPNAACHOCSCKDROSYCGQG* 2980.08 


























































Table 20- κ-PIVE toxiforms 
 
R D C C G V K L E M C H P C L C D N S C K N Y G K G 




    
D 
   
D * * * * 
 








 CCGVKLEMCHPCLCDNSCKNY 2705.06 
















 CCGVKLEMCHPCLCDNSCKNYGK* 2889.19 
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Table 21- κ-PIVF toxiforms 
 
D C C G V K L E M C H P C L C D N S C K K S G K 




    
D 
   
* * * * 
 


















 CCGVKLEMCHPCLCDNSCKKSGK* 2827.20 















Table 22- PIVH toxiforms 
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PIVH R D C C G V V M E E C H K C L C N Q T C K K K G 
        
O γ γ 
      
D E 
 
* * * * * 
 




















 CCGVVMEECHKCLCNQTCKKK* 2728.17 





























Table 23- Linear-P toxiforms 
LINEAR-P F Q P S A E N E E G K F R F F D K Q Q 
  
Z O 
              
E * 
 
Annotated Sequence MH+ [Da] 
 ZPSAENEEGKFRFFDKQ 2039.94 
 ZOSAENEEGKFRFFDKQ 2055.94 
 ZPSAENEEGKFRFFDKQQ 2168.00 




Table 24- Ile-Contryphan-P toxiforms 





Annotated Sequence MH+ [Da] 
     CVIWPWC 1020.44 
     CVIWOWC 1036.44 
    GCVIWPWC* 1076.48 
    GCVIWPWC 1077.46 
    GCVIWOWC 1093.46 
   LGCVIWPWC 1190.55 
  SLGCVIWPWC 1277.58 
ATSLGCVIWPWC 1449.66 
 
Table 25- Contryphan-P3 toxiforms 
Contryphan-P3 A T S L A C A I W T K C 
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Annotated Sequence MH+ [Da] 
     CAIWTKC 938.42 
    ACAIWTKC 1009.46 
ATSLACAIWTKC 1381.66 
 
Table 26- Contryphan-P4 toxiforms 
Contryphan-P4 C V Y W R K C 
 
Annotated Sequence MH+ [Da] 
CVYWRKC 1071.49 
 
Table 27- ψ-PIIIE toxiforms 
 
R H P P C C L Y G K C R R Y P G C S S A S C C Q R 
   
O O 
          
O 
        
E * 
 
Annotated Sequence MH+ [Da] 
  OCCLYGKCRRYOGCSSASCCQ 2659.04 
   CCLYGKCRRYOGCSSASCCQR* 2701.11 
HOOCCLYGKCRRYOGCSSASCC 2781.09 
  PCCLYGKCRRYPGCSSASCCQR* 2782.17 
  PCCLYGKCRRYOGCSSASCCQR* 2798.16 
  OCCLYGKCRRYPGCSSASCCQR* 2798.16 
  OCCLYGKCRRYOGCSSASCCQR* 2814.16 
  OCCLYGKCRRYOGCSSASCCER* 2815.16 
  OCCLYGKCRRYOGCSSASCCQR 2815.16 
HOOCCLYGKCRRYOGCSSASCCQ 2909.16 
 OOCCLYGKCRRYOGCSSASCCQR* 2927.20 
 OOCCLYGKCRRYOGCSSASCCER* 2928.20 

















Table 28- PIIIG toxiforms 
PIIIG Q W G C C P V N A C R S C H C C 
 
Z 
      
D 
       
* 
 




Table 29- PIIIH toxiforms 
 
E I I L P A L G Q R K C C P L T A C K L G S G C K C C E 
 
Z 
            
O 
              
 
Annotated Sequence MH+ [Da] 
          KCCPLTACKLGSGCKCC 2059.87 
           CCPLTACKLGSGCKCCE 2060.81 
          KCCPLTACKLGSGCKCCE 2188.91 
          KCCOLTACKLGSGCKCCE 2204.90 




Table 30- PIIII toxiforms 
PIIII C C Q A Y C S R Y H C L P C C 
 
Annotated Sequence MH+ [Da] 
CCQAYCSRYHCLPCC 2094.75 
 
Table 31- δ-PVIA toxiforms 
 
E A C Y A P G T F C G I K P G L C C S E F C L P G V C F G 
      
O 
       
O 




Annotated Sequence MH+ [Da] 
        EACYAOGTFCGIKOGLCCSEFCLPGVC 3142.29 
          CYAOGTFCGIKOGLCCSEFCLPGVCFG* 3145.31 
EASKLDKKEACYAOGTFCGIKOGLCCSEFCLPGVCFG* 4244.90 
 
Table 32- PVIB toxiforms 
 

























 CTPYGGSCGVDSTCCGRCNVPRNKCE 3051.21 
 CTOYGGSCGVDSTCCGRCNVPRNKCE 3067.20 
 CTOYGGSCGVDSTCCGRCNVPRDKCE* 3067.20 
 CTOYGGSCGVDSTCCGRCNVORNKCE 3083.20 
 CTOYGGSCGVDSTCCGRCNVORDKCE* 3083.20 


























































Table 33- PVIC sites of modification **There were no spectral matches to the full PVIC 
mature peptide. Sites of modification were determined by matches to peptide fragments 
 




    
O 




            
* 
 
Table 34- PVID toxiforms 
 









             
* 
 





Table 35- PVIE toxiforms 
 
V G E F R G C A H I N Q A C N P P Q C C R G Y T C Q S S Y I P S C Q L 
           
D E 
  
D O O E 





Annotated Sequence MH+ [Da] 
     GCAHINQACNOOQCCRGYTCQSSYIOSCQL 3635.47 
















Table 36- PVIF toxiforms 
 
A T S N R P C K K T G R K C F P H Q K D C C G R A C I I T I C P 








             
* 
 






Table 37- PVIG toxiforms 
S T T K G A T S N R P C K I P G R K C F P H Q K D 




   
O 






C C G R A C I I T I C P 




Annotated Sequence MH+ [Da] 
    GATSNROCKIOGRKCFPHqKDCCGRACIITICP* 3947.85 
    GATSNRPCKIOGRKCFOHqKDCCGRACIITICP* 3947.85 
    GATSNROCKIOGRKCFPHQKDCCGRACIITICP 3947.85 
    GATSNRPCKIOGRKCFOHQKDCCGRACIITICP 3947.85 
    GATSNROCKIOGRKCFPHqKDCCGRACIITICP 3948.84 
    GATSNRPCKIOGRKCFOHqKDCCGRACIITICP 3948.84 
    GATSDROCKIOGRKCFOHQKDCCGRACIITICP* 3963.83 
    GATSNROCKIOGRKCFOHqKDCCGRACIITICP* 3963.85 
    GATSNROCKIOGRKCFOHQKDCCGRACIITICP 3963.85 








Table 38- κ-PVIIA toxiforms 
 
C R I P N Q K C F Q H L D D C C S R K C N R F N K C V 
    
O D E 
   
E 
































Annotated Sequence Thγo. MH+ [Da] 
GCOWDPWC* 1092.403 
 
Table 40- PIIA toxiforms 
PIIA C C C I R S D G P K C S R K C L S S F F C 
                      
 
Annotated Sequence MH+ [Da] 






Table 41- PVIIIA toxiforms 
 
G C S G S P C F K N K T C R D E C I C G G L S N C W 
      
O 
   
D 
     
γ 




G Y G G S R C G C K C T C R E 
Contryphan-P G C P W D P W C 
   
O 
    
* 
95 
      
 
        
 
Annotated Sequence MH+ [Da] 
 CSGSOCFKNKTCRDECICGGLSNCWCGYGGSRGCKCTCRE 4857.92 
 CSGSOCFKNKTCRDγCICGGLSNCWCGYGGSRGCKCTCRE 4901.90 
 CSGSPCFKNKTCRDECICGGLSNCWCGYGGSRGCKCTCRE 4841.91 
 CSGSPCFKDKTCRDECICGGLSNCWCGYGGSRGCKCTCRE 4842.92 
 CSGSPCFKNKTCRDECICGGLSDCWCGYGGSRGCKCTCRE 4842.89 
 CSGSOCFKNKTCRDECICGGLSDCWCGYGGSRGCKCTCRE 4858.90 
 CSGSOCFKDKTCRDECICGGLSNCWCGYGGSRGCKCTCRE 4858.90 
 CSGSOCFKDKTCRDECICGGLSDCWCGYGGSRGCKCTCRE 4859.92 
 CSGSOCFKDKTCRDγCICGGLSNCWCGYGGSRGCKCTCRE 4902.93 
 CSGSOCFKNKTCRDγCICGGLSDCWCGYGGSRGCKCTCRE 4902.93 
 CSGSOCFKDKTCRDγCICGGLSDCWCGYGGSRGCKCTCRE 4903.91 
 CSGSPCFKNKTCRDγCICGGLSNCWCGYGGSRGCKCTCRE 4885.87 






















Table 42- PVA toxiforms 
PVA G C C P K Q M R C C T L 








Table 43- PVB toxiforms 
PVB R D C C P E K M W C C P L 




   
O * 
 
Annotated Sequence MH+ [Da] 
 DCCPEKMWCCP 1542.53 
 DCCOEKmWCCP 1574.52 
 DCCOEKMWCCP 1558.52 
 DCCPEKmWCCP 1558.52 
 DCCOEKMWCCPL* 1670.62 
 DCCPEKmWCCPL* 1670.62 
 DCCPEKMWCCPL* 1654.63 
 DCCOEKMWCCOL* 1686.62 




Table 44- p21b sites of modification on the two identified peptides. **There were no 
spectral matches to the full PVIC mature peptide. Sites of modification were determined 
by matches to peptide fragments 
 F E L L P S Q D R S C C I R K T L E C L E N Y P G Q E S Q R A H Y 
A     O  E                 O     E    * 
 
 S I N A Q N N V R P A H D T C I N R L C F D P G F 





APPENDIX B: Chromatograms (TIC) of injected venom samples from  
C. purpurascens specimens. 
 
Figure 26- Total ion chromatogram from venom sample of specimen 1  
 




Figure 28- Total ion chromatogram from venom sample of specimen 3  
 
 




Figure 30- Total ion chromatogram from venom sample of specimen 5  
 
 




Figure 32- Total ion chromatogram from venom sample of specimen 7  
 
 




Figure 34- Total ion chromatogram from venom sample of specimen 9  
 
 




Figure 36- Total ion chromatogram from venom sample of specimen 11  
 
 




Figure 38- Total ion chromatogram from venom sample of specimen 13  
 
 




Figure 40- Total ion chromatogram from venom sample of specimen 15  
 
 




Figure 42- Total ion chromatogram from venom sample of specimen 17  
 
 




Figure 44- Total ion chromatogram from venom sample of specimen 19  
 
 




Figure 46- Total ion chromatogram from venom sample of specimen 21 
 
 




Figure 48- Total ion chromatogram from venom sample of specimen 23 
 
 




Figure 50- Total ion chromatogram from venom sample of specimen 25 
 
 








APPENDIX C: Features of the New Conopeptides in Conus purpurascens 
Here we describe the main features of newly discovered conopeptides in the injected 
venom of C. purpurascens. We include the sequence of the precursor proteins from the 
transcriptome and highlight the corresponding signal and mature sequences. We also 
show the annotated MS/MS spectra. When possible, we compare the novel C. 
purpurascens sequences to known conopeptides, which can confer putative structural and 
functional characteristics to these newly described peptides. 
Linear 
Linear-P belongs to the B2 Superfamily. This family of linear peptides is expressed in 
other Conus species based on sequences deposited in NCBI. A similar sequence, differing 
in a single residue, is expressed by C. ermineus (Sequence ID: AXL95472) [197], a close 
relative to C. purpurascens.  This is the first evidence of these B2 linear peptides in 
injected venom. 
 
Figure 53- Supplementary information for Linear-P. 1) full transcript with annotated 
signal sequence and mature peptide regions and 2) annotated MSMS spectra 
 
112 
One disulfide (C-C) 
Ile-contryphan-P belongs to the M superfamily. Ile-contryphan-P exhibits sequence 
homology to previously described leu-contryphan-P, except for a switch from L5 to W5. In 
general, contryphans are characterized by a conserved motif containing D-tryptophan or 
leucine and a single disulfide bond. Contryphans typically classify as part of the O2 
superfamily based on their signal sequence, however Ile-contryphan-P does not follow 
this trend. The molecular target of contryphans remain unclear. Here, Ile-contryphan-P 
was identified in 25 of the 27 venom samples, suggesting it has an important function that 
needs to be discerned. 
 
  
Figure 54- Supplementary information for Ile-Contryphan-P. 1) full transcript with 
annotated signal sequence and mature peptide regions and 2) annotated MSMS spectra 
 
Contryphan-P3 belongs to the M superfamily. Based on precursor analysis, these 
peptides form a new group of one disulfide peptides within the M superfamily [98]. 
Contryphan-P3 is also expressed by C. ermineus (Sequence ID: AXL95407) [197], but 
this is the first instance in venom. 
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Figure 54- Supplementary information for contryphan-P 1) full transcript with 
annotated signal sequence and mature peptide regions and 2) annotated MSMS spectra 
 
Contryphan-P4 is not expressed in the venom duct, it was first discovered by de novo 
sequencing using PEAKS software (Unpublished data from our lab). Like Contryphan P3, 
the same sequence is found in C. ermineus venom duct transcriptome and belongs to the 
M superfamily (Sequence ID: AXL95569). Contryphan-P3 and P4 have different 
expression patterns and cluster into separate cabals.  
Figure 54- Supplementary information for Contryphan-P3 1) mature peptide sequence 
as determined by de novo sequencing and 2) annotated MSMS spectra 
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Framework I (CC-C-C) 
PID belongs to superfamily A. The sequence of PID has been previously reported as a 
nucleic acid sequence from C. ermineus, E1.1 precursor (P03002, Conoserver). Here we 
provide the first evidence for the mature peptide in milked venom from C. purpurascens. 
The mature peptide exhibits homology to α-PIA (C. purpurascens) and to α-GID (C. 
geographus, P60274), suggesting PID will inhibit the nAChR [161, 198]. 
Figure 55- Supplementary information for PID 1) full transcript with annotated signal 
sequence and mature peptide regions, 2) annotated MSMS spectra and 3) sequence 
alignment with α-PID and α-GID.  
 
PIE belongs to superfamily A. Homology to α-conotoxin precursor Bt1.8 from C. betulinus 
(Sequence ID: A0A068B6Q6) and characterized α-GIC (Sequence ID: Q86RB2) that 
inhibits α3β2 receptors [199]. Interestingly, MS/MS data from this study identified PIE with 
an extended N-terminal tail lacked by characterized α-conotoxins.  
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Figure 56- Supplementary information for PIE 1) full transcript with annotated signal 
sequence and mature peptide regions, 2) annotated MSMS spectra, and 3) sequence 
alignment with α-GIC 
 
PIF is a new framework I conotoxin that was first sequenced de novo using PEAKS 
(Unpublished data). Because it was sequenced de novo, the superfamily is unable to be 
assigned. The mature peptide shows homology to EIIA from C. ermineus (Sequence ID: 
D4HRK4) which inhibits muscle subtype nAChRs [200]. PIF is also similar to α-PIB, a 





Figure 57- Supplementary information for PIF 1) mature peptide sequence as 
determined by de novo sequencing, 2) annotated MSMS spectra, and 3) sequence 
alignment with α-PIF and α-EIIA  
 
PIG is a framework I conotoxin that was sequenced de novo using PEAKS software 
(Unpublished data). We lack signal sequence information, however the mature peptide 





Figure 58- Supplementary information for PIG 1) mature peptide sequence as 
determined by de novo sequencing, 2) annotated MSMS spectra, and 3) alignment with 
α-PIA 
Framework II (CCC-C-C-C) 
PIIA exhibits cysteine framework II and belongs to the O3 Superfamily. A very similar 
sequence is found in the C. ermineus venom duct transcriptome (Sequence ID: 
AXL95373) [197]. There are no similar characterized conotoxins from which we can infer 
activity. It is important to note that there is an extra cystine pair upstream from the identified 
N-terminus, and it is possible that the mature peptide identified through our approaches 
was in fact a truncated version. If this extra cysteine pair is part of the mature peptide, it 





Figure 59- Supplementary information for PIIA 1) full transcript with annotated signal 
sequence and mature peptide regions and 2) annotated MSMS spectra 
 
Framework III (CC-C-C-CC) 
PIIIG belongs to the M superfamily that clusters with the motor cabal. It is an M1 mini-M 
with loops sizes 4/2/1 according to the number of residues between cysteine residues 
[125]. The mature peptide has very little sequence homology to other mini-Ms. The 
pharmacology of the mini-Ms remains unknown, despite their prevalence across Conus 
species [124].  
 
 
Figure 60- Supplementary information for PIIIG 1) full transcript with annotated mature 
peptide region and 2) annotated MSMS spectra 
 
PIIIH is an M superfamily conotoxin that clusters with the motor cabal. It is an M1 mini-M 
with loop sizes 4/5/1. PIIIH clusters with motor cabal toxins. It exhibits sequence homology 
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to a peptide expressed in the venom duct of fish-hunting cone snail C. magus (Sequence 
ID: QFQ61044), however there is no evidence of this peptide in the injected venom [202].  
 
 
Figure 61- Supplementary information for PIIIH 1) full transcript with annotated signal 
sequence and mature peptide regions and 2) annotated MSMS spectra 
 
PIIII is a mini-M (M2) from the M Superfamily. It is the only one of the 3 identified venom 
mini-Ms that clustered with lightning-strike cabal peptides. Similar transcripts are found in 
Turriconus species (ATF27414, ATF27651) [203], and in C. regius (P85021) [124]. These 
are all worm-hunting species, supporting previous evidence that C. purpurascens may 




Figure 62- Supplementary information for PIIII 1) full transcript with annotated signal 
sequence and mature peptide regions and 2) annotated MSMS spectra 
 
Framework IV (CC-C-C-C) 
PIVH belongs to the A superfamily. Its expression in the milked venom clusters closely 
with κ-PIVF and other lightning strike cabal toxins. PIVH shares ~60% homology with κ-





Figure 63- Supplementary information for PIVH 1) full transcript with annotated signal 
sequence and mature peptide regions 2) annotated MSMS spectra, and 3) alignment with 
κ-PIVF and κ-PIVE 
 
Framework V (CC-CC) 
PVB is a T Superfamily conotoxin expressed in both transcriptomes. Its expression in the 
milked venom clustered closely with other motor cabal peptides. PVB is the second T 
Superfamily peptide identified from C. purpurascens venom but shows limited sequence 
homology to PVA aside from the conserved cysteine framework. The same sequence is 
found in the transcriptome of C. ermineus (Sequence ID: AXL95476) [197]. The 
pharmacology of T superfamily conotoxins is not well defined, however, two framework V 




Figure 64- Supplementary information for PVB 1) full transcript with annotated signal 
sequence and mature peptide regions and 2) annotated MSMS spectra 
 
Framework VI/VII (C-C-CC-C-C) 
PVIB is an O1 Superfamily conotoxin. PVIB was identified in 21 of the 27 venom samples  
suggesting it plays an important role in prey capture. It falls within cluster 1 (lightning-strike 
cabal) and is expressed in the venom of all 7 specimens that form this cluster. PVIB has 
high homology to a sequence from the venom duct transcriptome of C. ermineus 
(Sequence ID: AXL95467) [197].  
 
 
Figure 64- Supplementary information for PVIB 1) full transcript with annotated signal 
sequence and mature peptide regions and 2) annotated MSMS spectra 
 
PVIC belongs to the O1 Superfamily.  It shows high homology (85%) to δ-PVIA, and the 
two share similar patterns of expression in the venom. Its sequence is also similar to δ-
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EVIB (Sequence ID: P69752). For this reason, it is likely PVIC will also target sodium 
channels [113] as part of the lightning-strike cabal. 
 
 
Figure 65- Supplementary information for PVIC A) full transcript with annotated signal 
sequence and mature peptide regions and B) alignment with δ-PVIA and δ-EVIB 
 
PVID belongs to the O1 Superfamily. It was previously reported as a nucleic acid 
sequence, P2b (Sequence ID: AAQ05866) [1], but this is the first time reported in the 
venom. It clusters within the lightning strike cabal. It closely resembles C. purpurascens 
nucleic acid sequence p2a  (Sequence ID: AAQ05865), and new peptides PVIF (p2c,  
AAQ05867), and PVIG [1]. It does not share homology to any peptides with known activity. 
It does not share significant homology to any peptides with known activity, however it has 




Figure 66- Supplementary information for PVID 1) full transcript with annotated signal 
sequence and mature peptide regions and 2) annotated MSMS spectra 
 
PVIE belongs to the O1 Superfamily. The mature peptide has little sequence homology to 
any characterized conotoxin but has high homology to a nucleic acid sequence from C. 
ermineus  (Sequence ID: AXL95668) [197]. Interestingly, it is the only framework VI/ O1 
Superfamily toxin that is expressed within cluster 2 (motor cabal).   
 
 
Figure 67- Supplementary information for PVIE 1) full transcript with annotated signal 
sequence and mature peptide regions and 2) annotated MSMS spectra 
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PVIF belongs to the O1 Superfamily. It was previously reported as a nucleic acid 
sequence, P2c (Sequence ID: AAQ05867) [1], but this is the first time reported in the 
venom. PVIF was only identified in the venom of one specimen. It closely resembles C. 
purpurascens nucleic acid sequences p2a (Sequence ID: AAQ05865), PVID (p2b, 
AAQ05866) and PVIG [1].  It clusters within the lightning strike cabal. It does not share 




Figure 68- Supplementary information for PVIF 1) full transcript with an annotated 
signal sequence and mature peptide regions and 2) annotated MSMS spectra 
 
PVIG is a new O1 Superfamily conotoxin. It closely resembles C. purpurascens nucleic 
acid sequences p2a  (Sequence ID: AAQ05865), PVID (p2b, AAQ05866) and PVIF (p2c,  
AAQ05867) [1]. PVIG clustered with the lightning-strike cabal, although was only identified 
in one specimen. It does not share significant homology to any peptides with known 





Figure 69- Supplementary information for PVIG 1) full transcript with annotated signal 
sequence and mature peptide regions, 2) annotated MSMS spectra, and 3) sequence 
alignment with PVIF, and PVID, and κ-PVIIA. 
 
Framework VIII (C-C-C-CXC-CXC-CXCXC) 
PVIIIA belongs to the S Superfamily of conotoxins and contains 5 disulfide bonds. It was 
identified in 25 of the 27 venom samples, and therefore likely has an important role in the 
venom that has yet to be revealed. It clusters closely with ψ-PIIIE and α-PIVA and is a 
major component of the motor cabal. There are few framework VIII conotoxins with known 
bioactivity; two target the nAChR (α-GVIIIB, α-RVIIA) [206, 207] and one targets the 
serotonin receptor (σ-GVIIIA) [208]. However, PVIIIA does not display high sequence 
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Figure 70- Supplementary information for PVIIIA 1) full transcript with annotated signal 
sequence and mature peptide regions, 2) annotated MSMS spectra, and 3) sequence 
alignment with σ-GVIIIA, α-GVIIIB, and α-RVIIIA 
 
Framework XXI (CC-C-C-C-CC-C-C-C) 
p21b was expressed in transcriptome B and its precursor sequence classifies it as part of 
the con-ikot-ikot family. It shows 91% identity to P21a, a previously described 10 cysteine, 
5-disulfide conotoxin [127]. P21a was not expressed in either transcriptome and was not 
detected in the milked venom. However, P21b was identified in 10 of the 27 venom 
samples. It clusters closely to PVB and PIIIH, both newly described here. A con-ikot-ikot 
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isolated from C. striatus targets the AMPA receptor and is presumed to contribute to the 
lightning strike cabal [209]. In this study, P21b expression in the venom clusters with motor 
cabal toxins, suggesting an alternative molecular target for the con-ikot-ikot family of 
knottin peptides.  
 
 
Figure 71- Supplementary information for p21b 1) full transcript with annotated signal 




APPENDIX D: Alignment of gastropod insulin superfamily proteins.  
 
A0A0B5ADV0|Con-Ins Me1 -------MATSSCFLLVTLG--LLLHVQQ-AFLHE-HTCSPSEP---AAPGGICGSNLAELHSFLCEKELEDY-------    
A0A0B5A8P4|Con-Ins G3  -------MTTSFYFLLVALG--LLLYVCQSSFGNQ-HTRNSDTP------KHRCGSELADQYVQLCH------GK-----    
A0A0B5AC86|Con-Ins G3b -------MTTSFYFLLVALG--LLLYVCQSSFGNQ-HTRNSDTP------KHRCGSELADQYVQLCH------GK-----    
A0A0B5A7P2|Con-Ins G1C -------MTTSFYFLLMALG--LLLYVCQSSFGNQ-HTRTFDTP------KHRCGSEITNSYMDLCY------RK-----    
A0A0B5A8Q2|Con-Ins G1b -------MTTSFYFLLMALG--LLLYVCQSSFGNQ-HTRTFDTP------KHRCGSEITNSYMDLCY------RK-----    
A0A0B5AC95|Con-Ins G1a -------MTTSSYFLLMALG--LLLYVCQSSFGNQ-HTRTFDTP------KHRCGSEITNSYMDLCY------RK-----    
A0A0B5ADU4|Con-Ins T1  -------MTTSFYFLLMALG--LLLYVCQSSFGNQ-HTRNSDTP------KYRCGSEIPNSYIDLCF------RK-----    
A0A0B5ABD5|Con-Ins T3  -------MTTSFYFLLMALG--LLLYVCQSSFGNQ-HTRNSDTP------KYRCGSDIPNSYMDLCF------RK-----    
A0A0B5AC90|Con-Ins T2  -------MTTSFYFLLMALG--LLLYVCQSSFGNQ-HTRNSDTP------KYRCGSDIPNSYMDLCF------RK-----    
A0A0B5ABD9|Con-Ins G2  -------MTTSSYFLLVALG--LLLYVRQSFSTHE-HTCQLDDP---AHPQGKCGSDLVNYHEEKCEEEEARRGG-----    
A0A0B5ADT3|Con-Ins G2b -------MTTSSYFLLVALG--LLLYVRQSFSTHE-HTCQLDDP---AHPQGKCGSDLVNYHEEKCEEEEARRGG-----    
A0A0B5ABE4|Con-Ins Q1b -------MTTSSYFLLVALG--LLLYLCQSSFGTE-HTCEPGAS---PHPQGKCGPELAEFHETMCEVEESLQGG-----    
A0A0B5ABE6|Con-Ins Q1  -------MTTSSYFLLVALG--LLLYLCQSSFGTE-HTCEPGAS---PHPQGKCRPELAEFHETMCEVEESLQGG-----    
A0A0B5AC98|Con-Ins F1  -------MTTSSYFLLVTLG--LLLYVCRSSFGTE-HTCESDAS---PHPQGVCGSPLAEAVEAACELEEYLQGG-----    
A0A0B5A7N5|Con-Ins F2C -------MTTSSYFLLVALG--LLLYVCRSSFGSE-HTCESDAS---PHPQGVCGSPLAEAVEAACELEQSLQGG-----    
A0A0B5A7N1|Con-Ins F2b -------MTTSSYFLLVALG--LLLYVCRSSFGSE-HTCESDAS---PHPQGVCGSPLAEAVEAACELEESLQGG-----    
A0A0B5ADT9|Con-Ins F2  -------MTTSSYFLLVALG--LLLYVCRSSFGSE-HTCESDAS---PHPQGVCGSPLAEAVEAACELEESLQGG-----    
A0A0B5A8Q6|Con-Ins M1  -------MTTSSYFLLVALG--LLLYVCQSSFGGE-HVCGSNQP---NHPNGKCGSKMADYLEEQCEEEEAAHGG-----    
A0A0B5A7N8|Con-Ins Tx1 -------MTTSSYFLLVALG--LLLYVFQSSFGGE-HVCWLGDP---NHPQGICGPQVADIVEIRCEEKEAEQGG-----    
A0A0F7YYV0|ILP-1       -------MTTSSYFLLVALG--LLLYVCQSSFGGE-HVCWLDDP---NHPEGICGPQVSDIVEIRCEEKEAEQGG-----    
P91797|MIP-7           -----MNASVESCLTFTFVL--VALCVGLTIG-QQVNTCTMFSR---QHPRGLCGNRLARAHANLCFLLRNTYPDIFPRK    
Q9NDE7|MIP-1           MSKFLLQSHSANACLLTLLLT-LASNLDISLANFE-HSCNGYMR---PHPRGLCGEDLHVIISNLCSSLGGNR-------    
P80090|MIP-3           MASV--HLTLTKAFMVTVFLT-LLLNVSITRGTTQ-HTCSILSR---PHPRGLCGSTLANMVQWLCSTYTTSSKVK--R-    
P07223|MIP-1           MAGV--RLVFTKAFMVTVLLT-LLLNIGVKPAEGQFSACNINDR---PHRRGVCGSALADLVDFACSSSNQPAMVK----    
P25289|MIP-2           MVGV--RLVFTNAFVVTVLLT-LLLDVVVKPAEGQ-SSCSLSSR---PHPRGICGSNLAGFRAFICSNQNSPSMVK--R-    
P31241|MIP-5           MAGV--RLVFTKAFMVTVLLT-LLLNIGVKPAEGQFSACSFSSR---PHPRGICGSDLADLRAFICSRRNQPAMVK--R-    
A0A0B5A7M7|Con-Ins Im1 MA-----TSLLSPLLVAMLG--FLLHVHVARAGLE-HTCTLETRMQGAHPQGICGSKLPDIVHTVCQVMGRGY-------    
A0A0B5A8P8|Con-Ins Im2 MAL---TWPSSPPVLLTLLLSLLALQLCAVYGSYE-HTCTLATRSRGAHPSGICGRNLARIVSVLCTPRG--Y-------    
 
 
A0A0B5ADV0|Con-Ins Me1 --SGSALKKRGRPSR-----------------RMKRR-----------------------DFLSALKTRVKR--------    
A0A0B5A8P4|Con-Ins G3  --RNDAGKKRGRASP-----------------LWQRQ-----------------------GFLSMLKA--KR--------    
A0A0B5AC86|Con-Ins G3b --RNDAGKKRGRASP-----------------LWQRQ-----------------------GFLSMLKA--KR--------    
A0A0B5A7P2|Con-Ins G1C --RNDAGKKRGRASP-----------------LWQRR-----------------------GSLSQLKARAKR--------    
A0A0B5A8Q2|Con-Ins G1b --RNDAGEKRGRASP-----------------LWQRR-----------------------GFLSKLKARAKR--------    
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A0A0B5AC95|Con-Ins G1a --RNDAGEKRGRASP-----------------LWQRR-----------------------GSLSKLKARAKR--------    
A0A0B5ADU4|Con-Ins T1  --RNDAGKKRGRASP-----------------LWQRG-----------------------GSLSMLKARAKR--------    
A0A0B5ABD5|Con-Ins T3  --RNDAGKKRGQASP-----------------LWQRG-----------------------GSLSMLKARAKR--------    
A0A0B5AC90|Con-Ins T2  --RNDAGKKRGQASP-----------------LWQRG-----------------------GSLSMLKARAKR--------    
A0A0B5ABD9|Con-Ins G2  --TNDGGKKRRRASP-----------------LWKRR-----------------------RFLSMLKARAKR--------    
A0A0B5ADT3|Con-Ins G2b --TNDGGKKRRRASP-----------------LRKRR-----------------------RFISMLKARAKR--------    
A0A0B5ABE4|Con-Ins Q1b --TDDARKKRGRASL-----------------LRKRR-----------------------GFLSMLKARAKR--------    
A0A0B5ABE6|Con-Ins Q1  --TDDARKKRGRASL-----------------LRKRR-----------------------GFLSMLKARAKR--------    
A0A0B5AC98|Con-Ins F1  --TG---KKRGRASP-----------------LRKRR-----------------------AFLSMLKARAKR--------    
A0A0B5A7N5|Con-Ins F2C --TG---KKRGRASL-----------------LRKRR-----------------------AFLSMLKARAKR--------    
A0A0B5A7N1|Con-Ins F2b --TG---KKRGRASL-----------------LRKRR-----------------------AFLSMLKARAKR--------    
A0A0B5ADT9|Con-Ins F2  --TG---KKRGRASL-----------------LRKRR-----------------------AFLSMLKARAKR--------    
A0A0B5A8Q6|Con-Ins M1  --TNDARATTGRALS-----------------LSKRR-----------------------GFLSMLKRRGKR--------    
A0A0B5A7N8|Con-Ins Tx1 --ANNARANTGRTSS-----------------LMKRR-----------------------GFLSLLKKRGKR--------    
A0A0F7YYV0|ILP-1       --ANNARAYTGRTSS-----------------LMKRR-----------------------GFLSLLKKRGKR--------    
P91797|MIP-7           RSVDNTFEKV-YSIPLSVLAELDLSDDDWGAYVSKKDIPYRSETNGLSGANFESSAFDKQLELPAMKSTTSQLFRILKLR   
Q9NDE7|MIP-1           -----RFL---AKYMVKRD-TENVNDKLRGILLNKKE------------------------AFSYLTKR-----------   
P80090|MIP-3           QAE-----------------PDEEDDAMSKIMISKKR------------------------ALSYLTKR-----------    
P07223|MIP-1           -----------------RNAETDLDDPLRNIKLSSES------------------------ALTYLTKR-----------    
P25289|MIP-2           DAETGWLL---PETMVKRNAETDLDDPLRNIKLSSES------------------------ALTYLTKR-----------   
P31241|MIP-5           DAETGWLL---PETMVKRNAQTDLDDPLRNIKLSSES------------------------ALTYLTKR-----------   
A0A0B5A7M7|Con-Ins Im1 --AGGQRQLRKRTSMIDSDDMEAEGGSRGGFLMSKRR------------------------ALSYLQKETNPL--VMAGY   
A0A0B5A8P8|Con-Ins Im2 --VSNWFTK--RSAP-NKPAETFVDQNLRGVLLNKRE------------------------ALSYLRPR-----------   
 
 
A0A0B5ADV0|Con-Ins Me1 KEGRSVKRSPTSGMSCECCKNSCDAEEILEYCPPLPSS----------------------                       
A0A0B5A8P4|Con-Ins G3  NEAFFLQRD-GRGIVEVCCDNPCTVATLRTFCH---------------------------                       
A0A0B5AC86|Con-Ins G3b NEAFFLQRD-GRGIVEVCCDNPCTVATLMTFCH---------------------------                       
A0A0B5A7P2|Con-Ins G1C NGAFHLPRD-GRGVVEHCCHRPCSNAEFKKYCS---------------------------                       
A0A0B5A8Q2|Con-Ins G1b NGAFHLPRD-GRGVVEHCCHRPCSNAEFRKYCG---------------------------                       
A0A0B5AC95|Con-Ins G1a NGAFHLPRD-GRGVVEHCCHRPCSNAEFKKYCG---------------------------                       
A0A0B5ADU4|Con-Ins T1  NEAFHLQRA-HRGVVEHCCHRPCSNAEFKKFCG---------------------------                       
A0A0B5ABD5|Con-Ins T3  NEAFHLQRA-HRGVVEHCCKRACSNAEFMQFCGNS-------------------------                       
A0A0B5AC90|Con-Ins T2  NEAFHLQRA-HRGVVEHCCYRPCSNAEFKKFCG---------------------------                       
A0A0B5ABD9|Con-Ins G2  TG--------YKGIACECCQHYCTDQEFINYCPPVTESSSSSSSAA--------------                       
A0A0B5ADT3|Con-Ins G2b RG--------YQGIACECCQHYCTDQEFINYCPPVTESSSSSSSAV--------------                       
A0A0B5ABE4|Con-Ins Q1b NEASPLPRA-GRGIVCECCKNSCTYEEITEYCPPVTEGSG--------------------                       
A0A0B5ABE6|Con-Ins Q1  NEASPLPRA-GRGIVCECCKNSCTYEEITEYCPPVTEGSG--------------------                       
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A0A0B5AC98|Con-Ins F1  NEASPLQRS-GRGIVCECCKNHCNIEELTEYCPPVTEGSG--------------------                       
A0A0B5A7N5|Con-Ins F2C NEASPLQRS-GRGIVCECCKNHCNIEELTEYCPPVTEGSG--------------------                       
A0A0B5A7N1|Con-Ins F2b NEASPLQRS-GRGIVCECCKNHCNLEELTEYCPPVTEGSG--------------------                       
A0A0B5ADT9|Con-Ins F2  NEASPLQRS-GRGIVCECCKNHCNIEELTEYCPPVTEGSG--------------------                       
A0A0B5A8Q6|Con-Ins M1  NEASPLQRA-GRGIVCECCKNHCTDEEFTEYCPHVTESG---------------------                       
A0A0B5A7N8|Con-Ins Tx1 DEGSPLQRS-GRGIVCECCKHHCTKEEFTEYCH---------------------------                       
A0A0F7YYV0|ILP-1       DEGS-LQRS-GRGIVCECCKHHCTKEELTEYCH---------------------------                       
P91797|MIP-7           GSRLKREVMAEPSLVCDCCYNECSVRKLATYC----------------------------                       
Q9NDE7|MIP-1           --------EASGSITCECCFNQCRIFELAQYCRLPDHFFSRISRTGRSNSGHAQLEDNFS                       
P80090|MIP-3           --------ESRPSIVCECCFNQCTVQELLAYC----------------------------                       
P07223|MIP-1           --------QGTTNIVCECCMKPCTLSELRQYCP---------------------------                       
P25289|MIP-2           --------QRTTNLVCECCFNYCTPDVVRKYCY---------------------------                       
P31241|MIP-5           --------QRTTNLVCECCYNVCTVDVFYEYCY---------------------------                       
A0A0B5A7M7|Con-Ins Im1 ERRGIQKRHGEQGITCECCYNHCSFRELVQYCN---------------------------                       
A0A0B5A8P8|Con-Ins Im2 EPRATRGTFGSQGITCECCFNQCTYYELLQYCN---------------------------                       
 
Figure 72- Alignment of gastropod insulin superfamily proteins. Sequences are from InterPro database (reviewed). 
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